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Summary of used abbreviations  
 
ACN      Acetonitrile 
ADA      American Diabetes Association 
ANOVA     Analysis of variance 
BIPM     “Bureau International des Poids e Mesures” (International Bureau of    
   Weights and Measures) 
BSA      Bovine serum albumin 
CEN     Comité Européen de Normalisation (“European Committee for    
    Standardization”) 
CI       Confidence interval 
CID      Collision induced dissociation    
C-peptide     Connecting peptide 
CV      Coefficient of variation 
CVassay   Total imprecision of the routine immunoassay 
CVbetween     Between-run coefficient of variation 
CVmp Coefficient of variation of the method pair (total expected 
imprecision in a method comparison)  
CVRMP   Total imprecision of the reference measurement procedure 
CVtotal      Total coefficient of variation 
CVwithin      Within-run coefficient of variation 
ESI       Electrospray ionization 
ESI+   Positive electrospray ionization 
ESI-   Negative electrospray ionization 
HEPES      N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid 
HOMA      Homeostatic model assessment 
HPLC       High performance liquid chromatography 
IAC    Immunoaffinity chromatography 
ID-LC/tandem MS Isotope dilution-liquid chromatography/tandem mass spectrometry 
ID-MS      Isotope dilution-mass spectrometry 
IFCC    International Federation of Clinical Chemistry and Laboratory 
Medicine 
IgG      Immunoglobulin G 
IRP   International reference preparation 
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IS       Internal standard 
ISO      International Organization for Standardization 
IUPAC         International Union of Pure and Applied Chemistry 
IU   International unit 
JCTLM       Joint Committee for Traceability in Laboratory Medicine 
LC   Liquid chromatography 
LC/MS         Liquid chromatography/mass spectrometry 
LOD     Limit of detection 
LOQ      Limit of quantification 
MS       Mass spectrometry 
Mw      Molecular weight 
m/z      Mass to charge ratio 
RIA       Radio immunoassay 
RML      Reference measurement laboratory 
RMP      Reference measurement procedure 
rpm      Revolutions per minute 
SI-units     “Système International d’Unités“ (International System of Units) 
S/N       Signal to noise ratio 
SPE       Solid phase extraction 
SRM      Selected reaction monitoring 
TE      Total error 
TFA       Trifluoroacetic acid 
Th   Thomson (unit of m/z, where 1 Th=1 u/e) 
wESI-   Negative wrong-way-round electrospray ionization mode 
wESI+   Wrong-way-round electrospray ionization in the positive mode 
WHO     World Health Organization
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Definitions 
 
The definitions of the following terms were taken from the “Vocabulaire International de 
Métrologie – Concepts fondamentaux et généraux et termes associés“ (VIM) (i): 
 
• Accuracy (measurement ~ ) 
Closeness of agreement between a measured quantity value and a true quantity value 
of the measurand. 
Notes:  1. The concept ‘measurement accuracy’ is not given a numerical value,  
but a measurement is said to be more accurate when it offers a smaller 
measurement uncertainty. Measures of measurement accuracy are found 
in ISO 5725. 
2. The term “measurement accuracy” should not be used for ‘measurement 
trueness' and the term “measurement precision“ should not be used for 
‘measurement accuracy’. 
 
• Bias (measurement ~) 
Systematic measurement error or its estimate, with respect to a reference quantity 
value. 
 
• Detection limit or limit of detection 
Measured quantity value, obtained by a given measurement procedure, for which the 
probability of falsely claiming the absence of a component in a material is β, given a 
probability α of falsely claiming its presence. 
Notes:  1. IUPAC recommends default values for α and β equal to 0.05. 
2. The abbreviation LOD is sometimes used. 
 
• Influence quantity 
Quantity that, in a direct measurement, does not affect the quantity that is actually 
measured, but affects the relation between the indication and the measurement result. 
Notes: 1. An indirect measurement involves a combination of direct 
measurements, each of which may be affected by influence quantities. 
2. In the GUM, the concept ‘influence quantity’ is defined as in the 2nd 
edition of the VIM, covering not only the quantities affecting the measuring 
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system, as in the definition above, but also those quantities that affect the 
quantities actually measured. Also, in the GUM this concept is not 
restricted to direct measurements. 
3. It is also called “interference”, but there is no international consensus 
about the definition of this term. 
 
• Measurand 
Quantity intended to be measured. 
Notes: 1. The specification of a measurand requires description of the state of  
the phenomenon, body, or substance carrying the quantity, including any 
relevant component and the chemical entities involved. 
2. In the 2nd edition of the VIM and in IEC 60050-300:2001, the measurand 
is defined as the “quantity subject to measurement”. 
3. The measurement might change the phenomenon, body, or substance 
such that the quantity being measured may differ from the measurand. In 
this case adequate correction is necessary. 
4. In chemistry, “analyte”, or the name of a substance or compound, are 
terms sometimes used for ‘measurand’. This usage is erroneous because 
these terms do not refer to quantities. 
5. In chemistry, the measurand can be a biological activity. 
 
• Measurement 
Process of experimentally obtaining one or more quantity values that can reasonably 
be attributed to a quantity. 
Notes: 1. Measurement implies comparison of quantities or counting of entities. 
2. Measurement presupposes description of the quantity commensurate 
with the intended use of the measurement result, a measurement 
procedure, and a calibrated measuring system operating according to a 
specified measurement procedure. 
 
• Metrological traceability 
Property of a measurement result whereby the result can be related to a stated 
reference through a documented unbroken chain of calibrations, each contributing to 
the measurement uncertainty. 
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Notes:  1.  For  this  definition,  a   ‘stated reference’   can   be   a   definition   of   a  
measurement unit through its practical realization, or a measurement 
procedure including the measurement unit for a non ordinal quantity, or a 
measurement standard. 
2. Metrological traceability requires an established calibration hierarchy. 
3. Specification of the stated reference must include the time at which this 
reference was used, along with any other relevant metrological information 
about the reference, such as when the first calibration in the calibration 
hierarchy was performed. 
4. For measurements with more than one input quantity in the 
measurement model, each of the input quantities should itself be 
metrologically traceable and the calibration hierarchy involved may form a 
branched structure or a network. The effort involved in establishing 
metrological traceability for each input quantity should be commensurate 
with its relative contribution to the measurement result. 
5. Metrological traceability by itself does not ensure adequate 
measurement uncertainty or absence of mistakes. 
6. A comparison between two measurement standards may be viewed as a 
calibration if the comparison is used to check and, if necessary, correct the 
quantity value and measurement uncertainty attributed to one of the 
measurement standards. 
7. The abbreviated term “traceability” is sometimes used for ‘metrological 
traceability’ as well as for other concepts, such as ‘sample traceability' or 
‘document traceability’ or ‘instrument traceability’, where the history (‘trace’) 
of an item is meant. Therefore, the full term is preferred. 
 
• Precision 
Closeness of agreement between indications obtained by replicate measurements on 
the same or similar objects under specified conditions. 
Notes:  1. Measurement precision is usually expressed numerically by measures of 
imprecision, such as standard deviation, variance, or coefficient of variation 
under the specified conditions of measurement. 
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2. The ‘specified conditions’ can be repeatability conditions of 
measurement, intermediate precision conditions of measurement, or 
reproducibility conditions of measurement (see ISO 5725-5:1998). 
3. Measurement precision is used to define measurement repeatability, 
intermediate measurement precision, and measurement reproducibility. 
4. Sometimes “precision” is erroneously used to mean ‘measurement 
accuracy (2)’. 
 
• Repeatability (measurement ~) 
Measurement precision under a set of repeatability conditions of measurement. 
 
• Repeatability condition of measurement 
Condition of measurement in a set of conditions that includes the same measurement 
procedure, same operators, same measuring system, same operating conditions and 
same location, and replicate measurements on the same or similar objects over a 
short period of time 
Note: In chemistry, the term ‘intra-serial precision condition of measurement’ is 
sometimes used to designate this concept. 
 
• Reproducibility (measurement ~) 
Measurement precision under reproducibility conditions of measurement. 
Note: Relevant statistical terms are given in ISO 5725-2:1998. 
 
• Reproducibility condition of measurement 
Condition of measurement in a set of conditions that includes different locations, 
operators, measuring systems, and replicate measurements on the same or similar 
objects. 
Notes:  1. The different measuring systems may use different measurement  
procedures. 
2. A specification should give the conditions changed and unchanged, to 
the extent practical. 
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• Selectivity (~ of a measuring system) 
Capability of a measuring system, using a specified measurement procedure, to 
provide measurement results, for one or more measurands, that do not depend on 
each other nor on any other quantity in the system undergoing measurement. 
Notes: 1. In physics, there is only one measurand, the other quantities are of the 
same kind as the measurand, and they are input quantities to the 
measuring system. 
2. In chemistry, the measured quantities often involve different components 
in the system undergoing measurement and these quantities are not 
necessarily of the same kind. 
3. In chemistry, selectivity of a measuring system is usually obtained for 
quantities with selected components in concentrations within stated 
intervals. 
4. Selectivity as used in physics (see Note 1) is a concept close to 
specificity as it is sometimes used in chemistry. 
 
• Sensitivity 
Quotient of the change in the indication and the corresponding change in the value of 
the quantity being measured. 
Notes: 1. The sensitivity can depend on the value of the quantity being measured. 
2. The change considered in the value of the quantity being measured 
must be large compared with the resolution. 
 
• Trueness (measurement ~) 
Closeness of agreement between the average of an infinite number of replicate 
measured quantity values and a reference quantity value. 
Notes: 1. A reference quantity value can be a true quantity value of the measurand 
or an assigned quantity value of a measurement standard with negligible 
measurement uncertainty. 
2. Measurement trueness cannot be expressed numerically, but measures 
are given in ISO 5725. 
3. Measurement trueness is inversely related to only systematic 
measurement error. 
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4. The term “measurement trueness” should not be used for ‘measurement 
accuracy‘ and vice versa. 
 
• Validation 
Verification, where the specified requirements are adequate for a stated use. 
Note: 1. The ISO 9000 (ii) has another definition to this term: “Confirmation, 
through the provision of objective evidence, that requirements for a specific 
intended use or application have been fulfilled”. 
 
• Verification 
Provision of objective evidence that a given item fulfils specified requirements, taking 
any measurement uncertainty into consideration. 
Notes: 1. The item may be, e.g., a process, measurement procedure, material,  
compound, or measuring system. 
2. The specified requirements may be, e.g., that a manufacturer’s 
specifications are met. 
3. In legal metrology, verification pertains to the examination and marking 
and/or issuing of a verification certificate for a measuring instrument. 
4. Verification should not be confused with calibration or validation. 
5. In chemistry, verification of identity of entity involved, or of activity, 
requires a description of the structure or properties of that entity or activity. 
 
The following definitions were taken from the standard ISO 17511 (iii): 
 
• Analytical specificity 
Ability of a measurement procedure to measure solely the measurand. 
 
• Commutability of a material 
Degree to which a material yields the same numerical relationships between results of 
measurements by a given set of measurement procedures, purporting to measure the 
same measurable quantity, as those between the expectations of the relationships for 
the same procedures applied to those other types of material for which the procedures 
are intended. 
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The term evaluation is not officially defined by any organization but it is a generic term 
for any study that measures the performance capabilities of a method. An alternative term 
is study. 
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DEVELOPMENT OF REFERENCE MEASUREMENT 
PROCEDURES FOR THE DETERMINATION OF  
C-PEPTIDE AND INSULIN IN HUMAN SERUM 
___________________________________________ 
 
 
For a more detailed information on this topic see: 
 
- Thienpont LM, Van Uytfanghe K, Rodríguez Cabaleiro D. Metrological traceability of 
calibration in the estimation and use of common medical decision-making criteria. Clin 
Chem Lab Med 2004;42:842-50 [Review].  
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I.1. BACKGROUND 
 
I.1.1. Metrological considerations 
 
It has long been known that for comparability of analytical results in clinical chemistry a 
generally accepted coherent measurement or reference system is necessary. To fully 
understand the basis of such a system, the following considerations are necessary. 
 The full specification of a measurement in the clinical laboratory comprises the 
description of the following three elements, i.e., the system (e.g., blood serum), the 
component (also called analyte, e.g., insulin), and the kind-of-quantity (e.g., amount-of-
substance concentration) (1,2). All elements together are called the measurand (3). The 
value of a quantity, determined by a measurement, is expressed by both a number and an 
unit. As a consequence, in order to obtain comparable measurement results, it is a basic 
requirement that they are expressed in commonly accepted units. For this purpose, the 
international metrological society developed the “Système International d’Unités” (1), 
better known as SI-units. The “International Federation of Clinical Chemistry and 
Laboratory Medicine” (IFCC) recommended the use of the aforementioned units in clinical 
chemistry, at least for analytes of which the identity is unambiguously known (4). The units 
used most often are those for the mass concentrations, i.e., g/L and substance 
concentrations, i.e., mol/L. 
Note that as suggested before, in clinical chemistry many analytes lack an 
unequivocally defined entity with the consequence that they do not fit into the SI-system. 
Nevertheless, being clinically relevant analytes, they also require a common 
measurement unit for expression of laboratory measurement results. In response to that 
need, the World Health Organization (WHO) developed the concept of the International 
Unit (IU) (5) using the following principle. An International Standard material is prepared 
with state-of-the-art purification and identification techniques and its function is tested by 
the response of a biological system. The IU is then assigned by convention, e.g., one IU is 
assigned to one mg of preparation. Once defined, the IU is applied to all further 
International Reference Preparations (IRP). In this way, metrological consistency is 
achieved. 
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I.1.2. The reference measurement system: Metrological traceability chain and 
calibration hierarchy 
 
Traceability is defined as a “property of a measurement result whereby the result can be 
related to a stated reference through a documented unbroken chain of calibrations, each 
contributing to the measurement uncertainty” (3). For measurement results expressed in 
SI-units, this property is the mechanism to track the path of a measurement from the SI-
unit to the actual result. The mechanism consists of an unbroken chain of traceable 
comparisons, whereby each link has a known uncertainty of measurement, defined as the 
‘‘parameter characterizing the dispersion of the quantity values being attributed to a 
measurand, based on the information used" (3).  
The structure of such a hierarchical chain of comparisons, further referred to as 
the metrological traceability chain, is presented in Figure I.1. In general, it can be 
described as a multilevel hierarchy of alternating measurement procedures and calibration 
materials. The arrows indicate how these elements are combined: at each level, the 
calibration material on the left side is used to calibrate the measurement procedure on the 
right. The latter serves the purpose of assigning a value to the calibration material at the 
level below. In Figure I.1, the SI-traceability chain starts at the top with the definition of the 
appropriate SI-unit for the measurand (system, analyte, kind-of-quantity), followed by the 
primary realization of the SI-unit (via a primary reference measurement procedure (RMP) 
and a primary calibrator). The traceability chain ends with the end-user’s routine 
measurement procedure applied to produce a result from a sample. The SI-traceability 
chain shown in Figure I.1 is the most extensive one. To reduce the uncertainty that 
accumulates at each of the different levels, one might advocate the omission of pairs of 
consecutive levels of calibrator and procedure (e.g., the secondary calibrator and the 
manufacturer’s selected measurement procedure). 
The above described traceability chain and calibration hierarchy form the so called 
reference measurement system. The key to trueness of measurement results in clinical 
chemistry is the establishment of traceability of measurements to the highest international 
standards by a comprehensive reference measurement system (6). It should be 
mentioned that this standard is written in relation to the European legislation, laid down in 
the EC Directive on In-vitro Diagnostic Medical Devices (98/79/EC) and requiring that 
manufacturers demonstrate metrological traceability of their products (7). 
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Figure I.1. Extensive calibration hierarchy to ensure metrological traceability to the SI (adapted from EN/ISO 
17511) (6). 
 
I.1.3. Reference measurement procedures 
 
The International Vocabulary of Metrology (VIM) (3) defines a RMP as a “measurement 
procedure accepted as providing measurement results fit for their intended use in 
assessing measurement trueness of measured quantity values obtained from other 
measurement procedures for quantities of the same kind, or in characterizing reference 
materials”. In clinical chemistry the main purpose of RMPs is to make results of field 
assays metrologically traceable to the highest international standard or SI. In this way, the 
comparability of laboratory results independent of time, place and used measurement 
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system is achievable, as well as the use of common reference intervals and decision 
limits. 
The International Organization for Standardization (ISO) recommends that for 
standardization of physico-chemically well-defined analytes an accuracy-based higher 
order measurement procedure with traceability to the SI-unit should be preferably used. 
The prerequisites for a measurement procedure to be qualified as accuracy-based RMP 
are: it must be directly calibrated (matrix free) with primary calibrators, it is based on a 
matrix-independent measuring principle (absence of sample related effects) and it has 
either a smaller imprecision than the routine measurement procedure or performs a 
greater number of measurements (8). With respect to the method principle to be at the 
basis of a SI-traceable measurement procedure for organic analytes, isotope dilution-
liquid chromatography/tandem mass spectrometry (ID-LC/tandem MS) is a valid one 
(5,6,9). This is by virtue of the combination of 3 effects: compensation for possible losses 
of the analyte (e.g., adsorption and degradation of the analyte, incomplete recovery) and 
incontrollable variables during the measurement procedure (e.g., ion suppression) by the 
stable isotopically labeled analyte that is added to samples and calibrators in the earliest 
as possible phase; separation of the analyte from other matrix constituents in the 
chromatographic step; specificity of the mass spectrometric detection at m/z values 
characteristic for the analyte, or in case of tandem MS, for a precursor to product ion 
transition. In other words, an optimized ID-LC/tandem MS measurement procedure is 
capable of controlling the stability and recovery of the analyte during the entire 
measurement procedure and producing interference-free quantification of the analyte in 
accordance with its definition. 
For a particular RMP, the analytical requirements should, to a certain extent, be 
related to the medically required quality of the routine measurement procedure it intends 
to calibrate (8). It is obvious that to guarantee these performance specifications, a RMP 
should be performed under conditions of rigorous internal quality control. In addition, 
RMPs should be performed in competent reference measurement laboratories (RMLs) 
working under defined performance conditions (10), for example, as is the case in so-
called networks of RMLs (11). As already addressed above, the traceability chain is 
intended to make hierarchically lower routine measurement procedures traceable to the 
SI. Ideally, this requirement could be realized exactly in the same way as described 
previously for RMPs, i.e., by using primary calibrators as manufacturer’s working 
calibrators. However, most method principles at the basis of routine measurement 
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procedures severely hamper direct calibration due to commutability problems. The 
commutability problems come down to the fact that routine measurement procedures may 
have a different behavior with a calibrator than with a patient sample. A solution to that 
problem is to use matrix-matched calibrators, e.g. native samples with values assigned by 
a matrix-independent RMP, itself being calibrated with the primary calibrator (12). This 
calibration approach is also called ‘‘split-sample measurement design’’. Up to now, 
however, guidelines are missing for ‘‘valid’’ calibration using such a design. Indeed, before 
split-sample measurements are applied for calibration of a routine measurement 
procedure, it is essential that this procedure is proven sufficiently specific.  
The requirements of RMPs in terms of measurement principle and analytical 
performance specifications can be obtained from specific literature (13) and the ISO 
15193 (14). Since RMPs are per definition associated with reference materials (see 
traceability chain) and are performed in RMLs, it is also of interest mentioning the ISO 
15194 (describing reference materials) (15) and the ISO 15195 (specifying the required 
level of competence of a RML) (16).  
 
I.1.4. Current situation with regard to organizing the implementation of reference 
measurement systems 
 
The responsibilities for establishing the metrological traceability chain are as follows (6): 
the international and national institutions such as the International Bureau of Weights and 
Measures (BIPM), National Metrological Institutes and accredited RMLs are responsible 
for assigning values to the primary and secondary calibrators; documentation of the 
traceability of the end-user’s routine measurement procedure is the responsibility of the 
manufacturer and/or the end-user; everything in between is the responsibility of the IVD 
manufacturers. 
Up to this point it appears, at least on paper, that complying with the traceability 
requirement of the European legislation should work (7). However, to what extent have 
the elements of the necessary reference measurement systems been established? The 
answer to that question is that candidate RMPs, reference materials of ‘a higher order’ 
and RMLs exist, however, without official endorsement by an agency created by the 
European legislators. In response to this need, a ‘framework’ has recently been 
established for international recognition. The Joint Committee for Traceability in 
Laboratory Medicine (JCTLM) has been created through a “Declaration of Co-operation” 
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by the International Committee of Weights and Measures (CIPM) and BIPM, IFCC and the 
International Laboratory Accreditation Cooperation (ILAC), as principal 
promoters/stakeholders, together with other key stakeholders such as producers of 
certified reference materials, the IVD industry, proficiency testing organizers, regulatory 
bodies, etc. Meanwhile, the JCTLM has implemented a process whereby reference 
materials, RMPs and RMLs can be nominated and are assessed for conformity with 
appropriate international documentary standards (mainly the above mentioned ISO 
15193, 15194 and 15195). The results of this process are published already for reference 
materials and RMPs on the BIPM and IFCC websites (www.bipm.fr and www.ifcc.org) 
(17). Those for RMLs will be published soon. In addition, as required by the ISO 15195, 
proficiency testing surveys for RMLs are currently being organized on behalf of the IFCC, 
so that technical competence can be demonstrated. This mechanism of interlaboratory 
comparisons is comparable to that used in networks of RMLs. Future plans are to make 
an ‘International Recognition Arrangement’ that will be available to all interested 
stakeholders who make reference to the JCTLM framework and databases in any relevant 
documentation they produce. Last but not least, it should be mentioned that up to now the 
JCTLM has no legal status. Therefore, it is not yet clear whether the decisions made by 
this organization will be accepted by the European Commission. 
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I.2. OBJECTIVES OF THE RESEARCH 
 
Due to the world wide diabetes mellitus epidemic there is an increasing interest in the 
measurement of insulin and C-peptide. Insulin serum concentrations provide important 
information for the estimation of insulin secretion and resistance. For example, indices 
such as those derived from homeostatic model assessment (HOMA) are widely used as a 
measure of insulin resistance, sensitivity and beta-cell function in clinical practice, as well 
as in research or epidemiological studies. Also the pharmaceutical industry, currently 
involved in the development of new therapeutic tools for the treatment of diabetes type II 
patients, i.e., the so-called insulin sensitizers, is strongly interested in the HOMA insulin 
resistance indices. Likewise, C-peptide determination has multiple applications in clinical 
practice and research.  It is even accepted that C-peptide concentrations provide a more 
reliable reflection of the pancreatic function than insulin (18-20). 
Unfortunately, the demonstrated lack of between-assay comparability counteracts 
the aforementioned utility of insulin and C-peptide measurements and necessitates either 
testing under controlled analytical conditions or interpreting results against assay-specific 
reference intervals (18,21-29). For example, the C-peptide cut-point value of 0.5 µg/L, 
initially issued by Medicare and Medicaid regulations, had to be replaced by a value 
≤110% of the assay-specific lowest reference value (30); cut-off or area under the curve 
values used in the definition of fulminant type I diabetes mellitus or preservation of beta 
cell function still need to be accompanied by rigorous specification of the used 
immunoassay (19,31). Also the calculated indices from HOMA insulin resistance vary to a 
greater extent since they depend on the absolute insulin concentrations, hence, currently 
using those indices in big epidemiologic studies with pooling of data is impossible. In other 
words, the problem of limited comparability of data generally hinders the development of 
uniform clinical practice guidelines.  
 The statements given in the background section of this dissertation make it 
obvious that the solution to the lack of between-assay comparability is an accuracy-based 
standardization of both insulin and C-peptide assays. Also as explained before, the way to 
do the standardization is straightforward, i.e., by application of the SI-traceability chain 
comprising adequate RMPs and reference materials. However, to the best of our 
knowledge at the start of this dissertation, no such SI-traceability chain existed for insulin, 
nor for C-peptide. Consequently, the few attempts at standardization that have been 
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undertaken until now were all based on a different concept which, unfortunately, was likely 
to fail. 
In the case of insulin, in 1996 the American Diabetes Association (ADA) organized 
a task force on the standardization of insulin assays (26). The efforts started with the 
assessment of the comparability of insulin measurements between laboratories using 17 
insulin assays. Because significant variability in insulin values was obtained for the 
distributed samples, the task force tried to improve the situation by using the approach of 
a common calibration material and curve fitting procedure. Unfortunately, these steps did 
not succeed in reducing the variability, which was in fact no surprise because of the 
known risk of non-commutability of the calibration material used (32-34). Despite of 
calibration of immunoassays with such a common material and curve fitting, the assays 
may still give discrepant results on patient samples because of a different behavior with 
the latter versus with the calibrator (9). In addition, the approach does not account for the 
difference in specificity between immunoassays, which may be attributable to the 
heterogeneity in circulating insulin forms that react to a greater or lesser extent with the 
different antisera, or to cross-reactivity with, for example, proinsulin. As a consequence of 
the observed difference in assay bias, the task force concluded from this study that it was 
not recommendable to use different insulin assays within a population or research study, 
unless beforehand sufficient specificity and interassay comparability was ensured from, 
respectively, validation and interlaboratory comparison studies according to the task 
force's guidelines. In 2004, a follow-up of the study was done by the ADA in conjunction 
with the National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) and the 
Centers for Disease Control and Prevention (CDC). An international work group was 
convened to evaluate the specificity of different assays, to establish guidelines for assay 
acceptability, and to develop a standardization program to achieve uniform, accuracy-
based values (27). Again the work group started the new project by repeating the 1996 
study but with eleven more recent commercially available insulin assays. The report 
confirmed a second time that (27) "a common insulin reference preparation did not 
change the among-assay coefficient of variation and failed to improve harmonization of 
results among assays".  The work group also concluded that to provide a metrologically 
appropriate basis for the measurement of insulin, there was an urgent need of a RMP with 
an international standard defined in terms of mass.  
In parallel to the above study, a similar study in 2004 in the UK also was 
performed by a new clinical research network for diabetes (35). In this study also eleven 
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currently available commercial assays performed in different laboratories were involved. 
The conclusion of this network's recent report in 2007 (28) was that the source of 
discrepancies in results is likely due to multiple factors and not explainable by a single 
analytical performance characteristic. The group also observed that not all insulin assays 
have acceptable performance characteristics at concentrations as low as 12 pmol/L, as is 
needed for clinical use. Last but not least they appealed upon the development of a RMP 
for standardization, instead of the common calibrator approach.  
For C-peptide, already one decade ago, authoritative associations such as the 
ADA and the NIDDK also appealed to the professionals and the diagnostics industry for 
the urgent standardization of immunoassays (26, 36). Once again, in this case it was 
assumed that the approach of using a common calibration material would help, but it 
failed (22, 26). Despite this failure, it was repeated by a new working group (members of 
the NIDDK C-peptide Standardization Committee), but this time a WHO reference reagent 
and plasma were used to serve as common calibrator. The outcome of this latest study 
(29, 36) was that normalization of results against the WHO reference reagent did not 
improve comparability, but against plasma it did. Nevertheless, the study concluded that 
the improvement in comparability may be insufficient to fulfill the requirements of clinical 
trials and better be replaced by a valid standardization basis using an accuracy-based 
RMP. To the best of our knowledge, no further progress in this direction was made by the 
group (23, 37). 
  In summary, all aforementioned work groups (for C-peptide and insulin) agreed 
that a metrologically valid standardization basis was needed, i.e., comprising an accuracy-
based RMP, calibrated with an international primary calibrator defined in terms of mass 
and used to assign values to the manufacturer's working calibrator (see SI-traceability 
chain in Figure I.1). However, realizing that standardization makes no sense if the assay 
is not sufficiently valid from the analytical point of view, the work groups also defined 
assay performance criteria (27, 28) to be used in a preliminary validation process with the 
RMP. 
 The outcome and conclusions from the aforementioned studies stimulated our 
laboratory to make work of the development of the required standardization approach. 
Therefore, we aimed to develop a RMP for both C-peptide and insulin and to perform a 
split-sample comparison using a set of native samples with values assigned by our RMP 
(5,9). From our expertise with standardization of other analytes, we concluded that a RMP 
for peptides and small proteins best be based on ID-LC/MS, because it guarantees the 
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specific and accurate measurement of the analyte and allows direct calibration with a 
primary calibrator defined in terms of mass (5,6,9). 
Whereas our objectives for C-peptide would be realized entirely at the expenses of 
our laboratory (note that we started with C-peptide), the objectives for insulin were funded 
by the ADA in the form of a grant (38).  
Below, the specific features of our C-peptide and insulin objectives will be detailed.  
 
C-peptide 
With regard to the development of a RMP for C-peptide in serum, we decided to start from 
our previously developed ID-LC/tandem MS measurement procedure for the 
determination of C-peptide in urine (39). With the objective in mind to move from the urine 
to the serum matrix, it was obvious from the beginning that we would be faced with two 
major challenges: the need to increase specificity (serum is a much more complex matrix) 
and sensitivity (the concentrations of C-peptide in serum are 50 times lower than in urine). 
Since the same LC/tandem MS hardware had to be used, we decided to focus in 
particular on the specificity of the sample pretreatment procedure in order to improve the 
signal-to-noise (S/N) ratio and, hence, the limits of detection (LOD) and quantification 
(LOQ) after processing of a reasonable volume of serum. In addition, in comparison to 
previously published liquid chromatography-mass spectrometry (LC-MS) procedures for 
C-peptide in serum (40, 41), it became our aim looking for a robust LC/tandem MS 
measurement procedure with a relatively short total analysis time to achieve sufficient 
sample throughput and column life-time. To obtain the aforementioned objectives, the 
following detailed strategy was applied: 
 
- Collision-induced dissociation (CID) experiments for elucidation of the fragmentation 
pathway and selection of CID conditions for the final selected reaction monitoring 
(SRM). 
- Development and optimization of a sample preparation based on a two-step solid 
phase extraction (SPE) procedure and comparison with the SPE-based sample 
preparation procedures existing in the literature (40, 41). 
- Development and testing of an alternative sample preparation procedure based on 
immunoaffinity chromatography (IAC). 
- Optimization of the LC/tandem MS parameters for superior chromatography and 
sensitivity. 
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- Validation of the ID-LC/tandem MS procedure, using the two-step SPE as the sample 
preparation procedure. 
- Investigation of the method feasibility for the purpose of standardization by performing 
a method-comparison study with three representative commercial assays. 
 
Insulin 
Our objectives were to develop a sample preparation procedure that would, in 
combination with the good chromatographic resolution of the high performance liquid 
chromatography (HPLC) step prior to optimal CID tandem MS, account for the demands in 
specificity and S/N necessary for the quantification of insulin in physiological 
concentrations (LOQ). We applied also special efforts in order to achieve a RMP of the 
quality level as required by the performance specifications of the ADA. We based the 
development of our procedure on work that has been done before (40-43). However, only 
one method (40) had sufficient sensitivity and followed the principle of ID-MS, which is, as 
explained before, an essential feature for a RMP. In addition, this method employed an 
off-line HPLC purification with a 60-min separation time. Therefore, we aimed to improve 
the sample-preparation, the chromatography, and the mass spectrometric detection for 
the analysis of insulin in human serum. To reach these objectives, the following strategy 
was applied: 
 
- Development of a suitable sample preparation procedure. Two approaches were 
studied, one sample preparation based on a two-step SPE procedure, attempting to 
improve previously published methods (40, 41) and another based on IAC being a 
modification of previous methods in the literature (40, 42, 43). 
- Development of a sensitive LC/tandem MS procedure and comparison with previously 
published methods (40-43). CID experiments with different gases and instruments 
were performed in order to find conditions for more sensitive detection in the SRM 
mode. 
- Establish the link between the Sigma standard and the WHO insulin 1st IRP 66/304. 
- Validation of the ID-LC/tandem MS procedure using IAC as sample preparation 
procedure. 
- Investigation of the method feasibility for the purpose of standardization by performing 
a method-comparison study with four representative commercial assays. 
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CHAPTER II. 
 
DEVELOPMENT, VALIDATION AND APPLICATION 
OF A REFERENCE MEASUREMENT PROCEDURE 
FOR C-PEPTIDE IN SERUM 
___________________________________________ 
 
 
The development of the ID-LC/tandem MS RMP for serum C-peptide was published in: 
 
- Stöckl D, Rodríguez-Cabaleiro D, Thienpont LM. Collision-induced dissociation of the 
[M-2H]2- ion of C-peptide. Rapid Commun Mass Spectrom 2004;18:3140-1. 
 
- Rodríguez-Cabaleiro D, Stöckl D, Thienpont LM. Improvement of sample pretreatment 
prior to analysis of C-peptide in serum by isotope-dilution liquid chromatography/tandem 
mass spectrometry. Rapid Commun Mass Spectrom 2005;19:3600-2. 
 
 
The validation and application of the ID-LC/tandem MS RMP for serum C-peptide was 
published in: 
 
- Rodríguez-Cabaleiro D, Stöckl D, Kaufman JM, Fiers T, Thienpont LM. Feasibility of 
standardization of serum C-peptide immunoassays with isotope-dilution liquid 
chromatography-tandem mass spectrometry. Clin Chem 2006;52:1193-6.   
Chapter II. C-peptide: Introduction 
 
 
19 
II.1. INTRODUCTION 
 
II.1.1. Biosynthesis, secretion and metabolism of C-peptide and insulin in humans 
 
Although this is a chapter dedicated to C-peptide, it will deal with the biosynthesis, 
secretion and metabolism of both C-peptide and insulin (mainly in sections II.1.1., II.1.2 &  
II.1.3). The reason for this combined description stems from their close relationship in the 
systemic circulation, as a result of synthesis from the same precursor in equimolar 
amounts. 
C-peptide (31 amino acids; Mw 3020) and insulin (51 amino acids; Mw 5808) are 
synthesized in the rough endoplasmic reticulum of the beta-cells of the pancreatic islets of 
Langerhans. They are then transported to the Golgi apparatus, where they are packaged 
in membrane-bound granules. These granules move to the plasma membrane by a 
process involving microtubules, and their contents are expelled by exocytosis. C-peptide 
and insulin then cross the basal laminae of the beta-cell and neighboring capillary to reach 
the bloodstream (1). 
 Like other polypeptide hormones and related proteins that enter the endoplasmic 
reticulum, C-peptide and insulin are synthesized as part of a larger preprohormone. The 
gene for insulin and C-peptide is located on the short arm of chromosome 11 in humans. 
Preproinsulin has a 23-amino-acid signal peptide removed as it enters the endoplasmic 
reticulum. The remainder of the molecule is then folded, and the disulfide bonds are 
formed to make proinsulin (see Figure II.1). C-peptide is the “connecting” peptide between 
the A and B chains of insulin and facilitates the folding of the protein and then is detached 
in the granules before secretion. 
C-peptide and insulin are synthesized from their precursors by a process of 
enzymatic cleavage (Figure II.2). Two endopeptidases, prohormone convertases 2 and 3 
(PC2 and PC3), cleave the proinsulin molecule at two sites marked by pairs of dibasic 
amino acids. The type-1 endopeptidase (PC3) cleaves at the Arg31-Arg32 site at the 
junction of the B/C chains of proinsulin and the second endopeptidase (PC2) cleaves at 
the Lys64-Arg65 site, the proinsulin A/C junction. Both enzymes are calcium-dependent and 
have acidic pH optima, though their enzyme kinetics differ. Through the action of 
carboxypeptidase H there is a loss of basic amino acids at each site to give the ‘des’ 
forms of the partially processed proinsulins. When the cleavage at both sites is complete, 
C-peptide and insulin are produced. Gel chromatography studies have shown serum 
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Figure II.1. Schematic structure of human proinsulin with indication of its splitting in C-peptide and insulin. £ 
Indicates the positions where the internal standard (IS) of C-peptide was labeled with D8-Val. $ Indicates the 
positions where the IS of insulin was labeled with D10-Leu. 
 
C-peptide heterogeneity, which may arise either through in vivo metabolism and/or 
degradation on storage. This property has been confirmed by stable ID-MS (2). Normally, 
90-97% of the product released from the beta-cells is C-peptide and insulin in 
equimolecular amounts. The rest is mostly proinsulin. Insulin has the major biological 
activity though it has been proven in the last decade that C-peptide also has biological 
activity as will be described later (3-7). 
After secretion, C-peptide and insulin enter the portal circulation and are carried to 
the liver, the prime target organ. About 50% of secreted insulin is extracted and degraded 
in the liver; the residue is broken down by the kidneys. C-peptide is only partially extracted 
by the liver (and hence provides a useful index of the rate of insulin secretion), but is 
mainly degraded by the kidneys. The half-life of insulin in the circulation in humans is 
about 5 minutes. Insulin binds to insulin receptors and is internalized. It is destroyed by 
proteases in the endosomes formed by the endocytotic process. 
 
Chapter II. C-peptide: Introduction 
 
 
21 
 
 
Figure II.2. Scheme showing the processing of proinsulin to major intermediates and to C-peptide and insulin. 
Letters identify chains, small circles represent the amino acid residues at positions 31 and 32 (Arg-Arg) and 64 
and 65 (Lys-Arg). PC: proinsulin converting enzyme; CPH: carboxypeptidase H. 
 
II.1.2. Physiological effects of C-peptide and insulin 
 
As mentioned before, it has been suggested from experimental data and clinical studies 
performed during the last decade that C-peptide is a biologically active peptide (3-7). 
Clinical studies show that C-peptide administration in type I diabetes patients, who lack 
the peptide, results in improvement of diabetes-induced renal and nerve dysfunction. 
Molecular studies demonstrate binding to cell membranes, activation of intracellular 
signaling pathways, and specific end effects of importance for vascular endothelial 
function. These findings have prompted the hypothesis that C-peptide deficiency in type I 
diabetes may contribute to the development of microvascular complications, and that C-
peptide replacement, together with regular insulin therapy, may be beneficial in the 
treatment or prevention of these complications. 
PC3 
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Insulin is the major regulator of intermediary metabolism. The physiologic effects 
of insulin are far-reaching and complex (1, 8). They are conveniently divided into rapid, 
intermediate, and delayed actions, as listed in Table II.1.  
 
Table II.1. Principal actions of insulin (1). 
 
Rapid (seconds) Increased transport of glucose, amino acids, and K+ into insulin-sensitive cells. 
Intermediate (minutes) 
Stimulation of protein synthesis. 
Inhibition of protein degradation. 
Activation of glycolytic enzymes and glycogen synthetase. 
Inhibition of phosphorylase and gluconeogenic enzymes. 
Delayed (hours) Increase in mRNAs for lipogenic and other enzymes. 
 
The best known is the hypoglycemic effect, but there are additional effects on 
amino acid and electrolyte transport, many enzymes, and growth. The net effect of the 
hormone is storage of carbohydrate, protein, and fat; therefore, insulin is appropriately 
called the “hormone of abundance”. 
 
II.1.3. Clinical application of the measurement of C-peptide and insulin 
 
C-peptide 
Although, as explained above, insulin is the major regulatory hormone in the carbohydrate 
metabolism, it is generally accepted that C-peptide concentrations reflect the endogenous 
pancreatic insulin secretion more reliably in insulin-treated diabetics than the levels of 
insulin itself. C-peptide concentrations are not affected by factors limiting the utility of 
insulin levels, i.e., first-pass hepatic extraction, variable peripheral clearance and 
measurements hampered by anti-insulin antibodies or by insulin of exogenous origin in 
treated subjects. Therefore, to quantify the endogenous insulin secretion, C-peptide is 
measured basally, after fasting and after stimulation and suppression tests.  
 
The clinical indications for C-peptide measurement are multiple: 
• Direct assessment of the beta cell function via C-peptide testing is considered the 
most appropriate end point for clinical trials of therapies aimed at preserving or 
improving endogenous insulin secretion in type I diabetics (9-12).  
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• Detection and monitoring of the remission phase of type I diabetes.  
• Adjunct in the differential diagnosis of latent autoimmune diabetes mellitus of adults 
(LADA) and type-2 diabetes (13-15). 
• Although testing for C-peptide is never requested for the routine monitoring of 
diabetes, it is a valuable tool for the individual therapeutic decisions which are 
essential for an optimal long-term metabolic control (16,17). 
• In certain countries, C-peptide testing is also part of the qualification process for 
medical insurance coverage of insulin pump therapy. 
• Measurements of C-peptide is used as an aid in the differential diagnosis of 
hypoglycemia (factitious hypoglycemia and hypoglycemia caused by hyperinsulinism) 
to ensure an appropriate management and therapy of the patients. 
• Elevated C-peptide levels may result from increased beta-cell activity observed in 
hyperinsulinism, but also from renal insufficiency and obesity (18). 
• Contribution to the diagnosis of insulinoma (insulin-suppression test). 
• Prognostic index of fetal outcome in pregnant diabetic women. 
• Evaluation of insulin secretion in liver disease. 
• To assess the success of surgical removal of all or part of the pancreas and islet 
transplantation (18). 
• Correlation was also found between higher C-peptide levels and increasing 
hyperlipoproteinemia and hypertension (19). 
• Decreased C-peptide levels are also observed in starvation and Addison’s disease. 
 
Insulin 
The measurement of insulin is used in the following clinical investigations: 
• Diagnosis of hypoglycemia: serum insulin determinations are mainly performed in 
patients with symptoms of hypoglycemia. They are used to ascertain the 
glucose/insulin quotients and for clarification of questions concerning insulin secretion, 
e.g. in the tolbutamide test and glucagon test, in the evaluation of oral glucose 
tolerance tests or in hunger provocation tests. 
• Diagnosis of diabetes mellitus: insulin levels are normally low in patients with insulin-
dependent diabetes mellitus (IDDM) and are normal or elevated in patients with non-
insulin dependent diabetes mellitus (NIDDM). 
• Early detection of diabetes: the insulin response to the administration of glucose may 
be blunted well before the onset of clinical manifestations. 
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• Monitoring in persons with reduced glucose tolerance: in 3% of persons with reduced 
glucose tolerance, the metabolic state deteriorates towards diabetes mellitus over a 
period of time. Reduced glucose tolerance during pregnancy always requires 
treatment. The clearly elevated risk of mortality for the fetus requires intensive 
monitoring. 
• Follow-up and stabilization of insulin-treated diabetics: insulin assays can be useful at 
the onset of insulin therapy to evaluate the duration of action of various insulin 
preparations. 
• Determination of the quantity of free insulin in patients with anti-insulin antibodies: 
although the adequacy of pancreatic insulin synthesis is frequently assessed via the 
determination of C-peptide, it is still generally necessary to determine insulin. For 
example, therapeutic administration of insulins of non-human origin can lead to the 
formation of anti-insulin antibodies. In this case, measurement of the concentration of 
serum insulin shows the quantity of free (and hence biologically active) hormone, 
whereas the determination of C-peptide provides a measure of the patient’s total 
endogenous insulin secretion. 
• Predicting complications of Type II diabetes: the persistent elevation of insulin is a risk 
factor for the development of coronary disease. 
• Diagnosis of insulinoma: pancreatic beta-cell tumors may produce a state of 
hyperinsulinism leading to hypoglycemia. It is important for differential diagnosis of 
fasting hypoglycemia to discriminate between insulinoma and factitious hypoglycemia. 
In these applications, the glucose/insulin quotient may be more valuable than the 
insulin level alone 
• Other uses of insulin assays have been suggested by the finding of an increase in risk 
factors for coronary artery disease among healthy persons with hyperinsulinemia and 
normal glucose tolerance (20). 
• Also for forensic purposes and by the pharmaceutical industry. 
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II.1.4. Existing measurement procedures for serum C-peptide 
 
Routine analysis of C-peptide in the clinical laboratory is performed with a wide variety of 
commercial chemiluminescence (CLIA), radio (RIA) and enzyme linked (ELISA) 
immunoassays (21). Most of the systems are used for the determination of C-peptide in 
both urine and serum. In view of the synthesis and structure of C-peptide it becomes 
apparent that the main analytical challenge is the measurement of low concentrations in 
the presence of molecules of similar structure (21). For example, the 33-residue of C-
peptide (comprising two additional amino acids, lysine and arginine at the C terminus after 
incomplete processing of proinsulin) makes up 4-10% of the 31-residue C-peptide 
concentration. 
Chromatographic techniques are mainly used in the pharmaceutical industry and 
in research studies. HPLC followed by RIA of separated fractions (22, 23) or IAC followed 
by HPLC and RIA (24) have also been used. Procedures based on HPLC-MS after SPE 
or IAC for the analysis of C-peptide in serum have also been described in the literature (2, 
25, 26). Only the measurement procedures from Kippen et al. and Rogatsky E et al. (2, 
26) were of the ID-LC/MS type, which is, as described previously (see chapter I), an 
indispensable condition for a measurement procedure to be appointed as RMP. For more 
details on the existing methods, Table II.2 can be consulted. Notice that the method of 
Rogatsky et al. (26) was published after our study on C-peptide was finished. 
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II.1.5. Objectives 
 
The objective of this part of the dissertation was to develop a RMP for serum C-peptide 
and to apply it to the standardization of immunoassays. Previous experience gained at our 
laboratory on the general mass spectral and chromatographic behaviour of C-peptide and 
insulin (27-29) were of big utility. In particular, the previous development of a RMP for the 
determination of C-peptide in urine was of big use (30-32). 
 
Table II.2. Summary of the existing LC/tandem MS procedures for serum C-peptide. 
 
Author 
(reference) IS 
Sample 
preparation 
HPLC MS 
LODa 
(ng) 
Kippen AD 
et al. 
(2) 
[2H14] C-
peptide 
Sep-Pak® C18 
SPE 
or 
IAC + Sep-
Pak® C18 light 
SPE 
Nucleosil C18 (150x1 mm) 
 
60 min gradient of ACNb 
with 0.1% TFA 
Off-line 
Micromass VG single 
quadTM ESI+c 
 
Short scan 
m/z 1003-1016 
< 0.17 
Darby SM 
et al. 
(25) 
no 
Sep-Pak® C18 
SPE 
Hesperia Vydac C18 
(150x2.1 mm) 
 
10 min gradient of ACN 
with 0.04% TFA 
Finnigan MAT LCQTM 
Qtrap ESI+ 
 
SIM 
[M+3H]3+ 
< 4 
Rogatsky 
E et al. 
(26) 
[15N18] and 
[15N30] C-
peptide 
Sep-Pak® C8 
SPE 
2 dimensional HPLC 
Phenomenex Jupiter C5 
(100x2 mm) 
ACN with 0.1% TFA 
 
Varian Pursuit C18  
(50x2 mm) 
ACN/water/0.4% formic 
acid/1% isopropyl 
alcohol/2% methanol 
16 min run 
SCIEX API365TM 
API 4000TM 
ESI+ 
 
SIM 
[M+3H]3+ 
 
4·10-4 
 
aNote that 1 ng = 0.33 pmol 
bAcetonitrile (ACN) 
cPositive electrospray ionization (ESI+) 
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Because serum is a more complex matrix than urine, it requires a more intensive 
sample preparation procedure. In addition, concentrations of C-peptide in serum are 50 
times lower than in urine. In consideration of the above, a selective sample preparation 
procedure with good recovery had to be developed and improvement of the MS sensitivity 
had to be achieved. Since the same LC/tandem MS hardware had to be used, we focused 
in particular on the specificity of the sample pretreatment procedure in order to improve 
the S/N ratio and hence the LOD and LOQ after processing of a reasonable volume of 
serum. In addition, we aimed at a robust LC/tandem MS measurement procedure with a 
relatively short total analysis time to achieve sufficient sample throughput and column 
lifetime. 
Existing procedures for sample preparation, i.e., SPE with Sep-Pak® C18 
cartridges, described by Kippen et al. (2), Cohen et al. (33) and Darby et al. (25), were 
used as a starting point combined with our LC/tandem MS conditions (31). We 
investigated the potential of a two-step SPE, and afterwards of IAC. As an evaluation 
criterion, we mainly compared the subsequent LC/tandem MS ion chromatograms with 
those shown for the existing methods in the literature. For improvement of the mass 
spectrometric conditions, i.e., in terms of more selective and sensitive SRM, we studied 
the CID process in greater detail. 
Finally, the analytical performance characteristics of the candidate RMP based on 
ID-LC/tandem MS after two-step SPE were evaluated. To investigate the feasibility of this 
procedure for use in standardization, a split sample method comparison for parallel 
measurements of basal and stimulated C-peptide concentrations with three representative 
commercial assays was performed. 
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II.2. MATERIALS AND METHODS 
 
II.2.1. Specifications and requirements for a serum C-peptide candidate RMP 
 
There were no internationally recognized specifications for a candidate RMP for serum C-
peptide. Therefore, we chose “state-of-the-art” acceptance criteria. They were a total 
coefficient of variation (CVtotal) of 3.0% and a maximum deviation from target 
concentrations (trueness) of 5%. In view of the reference interval of C-peptide (1.1 – 3.6 
µg/L), a LOQ of 0.2 µg/L was considered acceptable.  
 
II.2.2. Calibrators, reagents, materials and sera 
 
Calibrators 
Proinsulin C-peptide fragment 33-63 and D8-Val7,10-C-peptide were obtained from 
Bachem. They were delivered in vials containing 500 µg of freeze-dried material and had 
a purity > 98% and a peptide content of 88.0% (C-peptide) and 86.9% (D8-Val7,10-C-
peptide) according to the manufacturer's information. We took the peptide content into 
account for calculation of the C-peptide content in the calibration solutions. All the 
solutions were prepared gravimetrically taking into account the density of the dilution 
solution. Densities were measured with a Mettler Toledo DA-110M density meter 
(Greifensee, Switzerland) and all solutions and standard materials were weighed in a 
Mettler Toledo AT261 Delta Range analytical balance that allowed measurements till to 
10-5 g. In this way, the concentration of all calibration solutions was known to four 
significant figures. Stock calibration solutions (250 mg/L) were prepared by adding 2 mL of 
0.03 mg/L (1%) protease-free bovine serum albumin (BSA) (Sigma) solution to the 500-µg 
C-peptide vial. From this stock solution two consecutive 1/5 dilutions in the same BSA 
solution were prepared to obtain respective concentrations of 50 mg/L and 10 mg/L (note 
that the lowest concentration tested to be stable in storage at -20 °C is 10 mg/L in 1% 
BSA (31)). Immediately after preparation, the latter solutions were divided into 70-µL 
portions in polypropylene vials and frozen at -20 °C until the day of analysis. On that 
occasion, three frozen vials were thawed and diluted with ultra pure water to obtain three 
different final calibration working solutions with a concentration of 30 µg/L. Once thawed, 
the portions were never reused. The calibration mixtures used for the ID-MS 
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measurements were prepared by gravimetrically controlled mixing of equivalent amounts 
of C-peptide and D8-Val7,10-C-peptide from the final working solutions. 
 
Reagents and materials  
All chemicals used were of superquality grade and purchased from Romil (Cambridge, 
UK) or Fluka (Buchs, Germany). Ultra-pure water (18.2mΩ) was prepared with an ELGA 
Maxima system (Elga Ltd., High Wycombe, UK). For SPE, Waters Sep-Pak® C18 3 cc 
(200 mg) and Oasis® MCX 1cc (30 mg) cartridges (Milford, MA, USA) were mounted on a 
JT Baker SPE-12G Column Processor® device (Phillisburg, NJ, USA). For IAC, Trizma® 
hydrochloride, Trizma® base, sodium azide and ammonium acetate were purchased from 
Sigma-Aldrich. The IAC-gel was prepared in collaboration with the Department of Clinical 
Medicine, Division of Clinical Chemistry, Biomedicum Helsinki, University of Helsinki 
(Finland). A mouse monoclonal antibody with an affinity constant of 1x108 M-1 (Biodesign 
International, Saco, ME, USA) was coupled to cyanogen-bromide-activated Sepharose 
(GE Healthcare, Diegem) with a capacity of 2 mg IgG/mL (0.5 mL per column). The 
procedure used for the preparation of the IAC-gel was done exactly as described by 
“Affinity Chromatography. Principles and Methods” (34). SPE after IAC was done with 
Sep-Pak® C18 1 cc (50 mg) cartridges.  
 
Sera 
The sera used during the development and optimization experiments came from the blood 
transfusion center from the Flanders Red Cross in Leuven. They were handled according 
to the local Ethical Committee guidelines. For internal quality control during the method 
comparison studies two supplemented serum pools were used (concentrations 4.1 µg/L 
and 14.8 µg/L). For the method comparison, samples were obtained from Ghent 
University Hospital from 15 ambulatory patients (2 men and 13 female, aged between 18 
and 64 years) who had been subjected to an oral glucose (75 g) tolerance test after 
overnight fasting. Blood was drawn before the glucose load and after 30, 60, 120 and 180 
min. The test was ordered by the endocrinologist for assessment of glucose tolerance, 
glucose handling and beta-cell function in subjects with morbid obesity and/or other risk 
factors for glucose resistance and intolerance. Handling of patient serum samples was 
performed according to the local Ethical Committee guidelines. Blood was drawn into 
Venosafe VF-106SAS tubes (Terumo) and allowed to clot at room temperature for at least 
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30 min. Serum was obtained by centrifugation at 1500 g for 10 min in a Jouan C412 
centrifuge (Thermo Electron Corporation).  
 
II.2.3. Instrumentation 
 
The LC/tandem MS instrument used was a Micromass VG Quattro IITM triple quadrupole 
MS (Altrincham, UK) equipped with a megaflow electrospray probe. It was coupled to a 
Kontron Instruments Model 325 HPLC system (Milan, Italy), equipped with an 
autosampler 465. Chromatography was performed on a Hamilton PRP-3 column (50 x 2.1 
mm, 3 µm particle size, 300 Å pore size) (Reno, NV, USA). Nitrogen was used as drying 
and nebulising gas at a flow rate of 450 and 14 L/h, respectively. 
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II.2.4. Analytical procedure for serum C-peptide 
  
Overview 
The developed sample preparation procedure for the determination of C-peptide in serum 
consisted of dilution of the serum and immediate purification by two-step SPE. The first 
step was based on a reverse phase interaction and the second step on a mixed reverse 
phase-cation exchange interaction. The final eluate was dried under nitrogen and the 
dried residue was redissolved and quantified via LC/tandem MS. A schematic 
representation of the procedure can be seen in Figure II.4.A. 
 
Sampling and calibration procedure 
The analysis started with gravimetric sampling of the serum (between 0.3 mL (minimum) 
and 2.5 mL (maximum)) and addition of D8-Val7,10-C-peptide in an equivalent amount to 
the endogenous C-peptide to obtain a 1:1 isotope ratio. At the same time three different 
standard working solutions were prepared having an approximate concentration of 30 
µg/L. Subsequently, three calibration mixtures (C-peptide/ D8-Val7,10-C-peptide) with each 
of the standard working solutions were prepared. Immediately after preparation, the 
calibration mixtures were evaporated to dryness at 50 °C under nitrogen. 
The calibration procedure was based on the principle of one point calibration (35). 
This calibration procedure, in combination with isotope dilution, provides the best results 
when it is done with a 1:1 isotopic ratio. The measurement procedure consisted of the 
analysis of three calibrators followed by the analysis of four samples, three calibrators and 
so on. This alternation of calibrators and samples was done to compensate any eventual 
drift in the response of the instrument. 
 
Two-step SPE sample preparation procedure 
After adding the IS and equilibration of the mixture during one hour at room temperature, 
a 1:1 dilution with 0.3% aqueous acetic acid (AcOH) was performed prior to SPE with 
Sep-Pak® C18 3 cc and Oasis® MCX 1 cc. Sep-Pak® C18 cartridges were preconditioned 
by consecutive wetting with 4 mL of ACN and 0.3% AcOH. After the diluted serum 
samples were loaded, they were washed with 2 mL 20/80/0.3 (v/v/v) ACN/water/AcOH 
and eluted with 1.5 mL 50/50/0.3 (v/v/v) ACN/water/AcOH. Oasis® MCX cartridges were 
preconditioned by consecutive wetting with 2 mL ACN and 0.1% trifluoro acetic acid (TFA) 
in water. In order to reduce the organic concentration, the extracts were diluted with 1.5 
mL of 0.1% TFA in water prior to loading onto the Oasis® MCX cartridges. Elution was 
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done with 1.5 mL of 50/50/0.3 (v/v/v) ACN/water/TFA. Finally, the extracts were 
evaporated to dryness at 50 °C under nitrogen and stored at -20 °C until analysis. Note 
that the calibration mixtures were not submitted to the sample pretreatment procedure.  
  
LC/tandem MS measurement procedure 
The evaporated extraction residues were reconstituted with 50 µL of 15/85/0.02 (v/v/v) 
ACN/water/TFA and centrifuged during 5 min at 5000 rpm before injection of 40 µL into 
the LC/tandem MS system. Chromatography was performed with a Hamilton PRP-3 
column (50 x 2.1 mm, 3 µm particle size, 300 Å pore size), in a total run time of 12 min, 
i.e., 5 min gradient elution from 15 to 35% ACN 0.02% TFA, followed by a fast increase (1 
min) of the ACN concentration to 70%. These conditions were maintained during 2 min for 
column cleaning. Finally, a 3 min re-equilibration with the starting eluent was performed. 
At a flow rate of 0.3 mL/min, the elution time of C-peptide and its isotopically labelled 
analogue from the PRP-3 column was ~4.5 minutes.  
ID-MS measurements were performed in the negative electrospray tandem MS 
mode monitoring the transitions from m/z 1509.2 to 183.8 (C-peptide) and m/z 1517.1 to 
183.8 (labelled analogue). The tandem MS conditions were: collision gas argon 3x10-3 
mbar, CID energy 80 eV; cone 75 V, capillary -4 kV, and source temperature 175 °C. The 
scan times were adapted in order to have at least 15 cycles per peak. Dwell times were 
set at 0.55 sec with an interchannel delay of 0.06 sec.  
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Figure II.3. Schematic representation of the HPLC-gradient 
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II.2.5. Comparison with sample preparation procedures in the literature 
 
The procedures of Kippen et al. (2) and Darby et al (25) were reproduced together with 
our two-step SPE procedure using the same serum pool and the extracts obtained were 
measured under identical HPLC-MS conditions. For a schematic representation of our 
sample preparation procedure and the procedures previously described in the literature 
see Figure II.4.A and Figure II.4.B and C, respectively. Our procedure was already 
described in detail in Chapter II.2.4, the other procedures are described in detail below. 
 
Procedure according to Kippen et al.  
A schematic representation of this procedure can be seen in Figure II.4.B. After being 
diluted with 5 ml of 0.1% TFA in water, the serum samples (1 ml) were filtered through a 
0.45-µm sterile filter (Millipore Corp., Billerica, MA, USA). Sep-Pak® C18 cartridges were 
washed with ACN and then equilibrated in 0.1% TFA in water. The serum was passed 
back and forth through the cartridge three times at ~1 ml/min using polypropylene 
syringes fixed at either end. Cartridges were washed with 4 mL of 20/80/0.1 (v/v/v) 
ACN/water/TFA and 80/20 (v/v) ACN/dichloromethane. Elution was done with 50/50/0.1 
(v/v/v) ACN/water/TFA, and the solutions were freeze-dried. 
 Samples were redissolved in 120 µL of 0.1% TFA. HPLC was performed with a 
microbore Nucleosil 300-Å C18 column (1 x 150 mm) (Machery-Nagel, Düren, Germany). 
A gradient from 22 to 36% ACN with 0.1% TFA over 60 min at 0.04 mL/min was 
performed. The aliquots collected were freeze-dried. Aliquots were reconstituted in 10 µl 
of 50/49/1 (v/v/v) methanol/water/AcOH and injected via infusion into the electrospray 
ionization-mass spectrometer (ESI-MS) system. The samples were then analyzed by 
performing small scans in positive ionization mode using either: (a) a Fisons Instruments 
VG-Trio 2000TM single quadrupole instrument (Altrincham, UK) at a flow of 2 µl/min and a 
scan cycle of 10 s or (b) a Micromass VG-Platform IITM single quadrupole instrument at a 
flow of 10 µl/min and a scan cycle of one second. The spectrum was scanned to cover the 
most intense signals of the target analyte and its IS, whereas the large carrier signal was 
designed to be out of this scan range. 
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Figure II.4. Schematic representation of the developed sample preparation procedure in comparison with the 
others in the literature. 
 
 
Procedure according to Darby et al. 
A schematic representation of this procedure is presented in Figure II.4.C. Darby et al. 
published the following method for analysis of C-peptide in serum samples. Five milliliters 
of plasma were diluted 1:1 with 0.3% AcOH in water. Sep-Pak® C18 cartridges were 
preconditioned with 5 mL of ACN and 5 mL of 0.3% AcOH in water. The cartridges were 
washed with 2 mL of 20/80 (v/v) ACN/0.3% AcOH in water. Elution was performed with 2 
mL of 40/60 (v/v) ACN/0.3% AcOH in water, and the solution was freeze dried. 
 HPLC was performed with a 2.1x50 mm Grace Vydac C18 column (Hesperia, CA, 
USA). A gradient from 20 to 40% ACN with 0.04% TFA over 10 min at 0.3 mL/min was 
performed. Measurements were done on a Finnigan MAT LCQ quadrupole ion trap (San 
Jose, CA, USA). The MS was set to measure in SIM  the [M+3H]3+ ion. 
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Protocol for the comparison between procedures 
For practical reasons, the sample preparation procedure of Kippen et al. was adapted (2, 
33). Sep-Pak® C18 3 cc cartridges were preconditioned with 5 mL of pure ACN and then 
with 0.1% TFA in water. The serum samples (2.5 mL) were diluted 1:1 with 0.1% TFA in 
water, and the resulting solution was applied to the cartridge. The eluate was collected 
and passed through the cartridge a second time (both times at a rate of ~1 mL/min). Then, 
a three-step washing procedure was performed, i.e., first with 2 mL of 20/80/0.1 (v/v/v) 
ACN/water/TFA, followed by 2 mL of 1% TFA in water, and then with 2 mL of 80/20 (v/v) 
ACN/dichloromethane. After the last washing step, an additional 2 mL of 20/80/0.1 (v/v/v) 
ACN/water/TFA were applied to remove residual dichloromethane (33). For elution, 2 mL 
of 50/50/0.1 (v/v/v) ACN/water/TFA were used. 
Aliquots of 2.5 mL from a serum pool were processed according to the three 
sample preparation procedures. The serum pool had an approximate concentration of 0.6 
µg/L. After sample preparation, the final SPE extracts were evaporated to dryness at 50°C 
under nitrogen. Afterwards, the residues were reconstituted with 50 µL of 15/85/0.02 
(v/v/v) ACN/water/TFA and centrifuged before injection of 40 µL of the resulting solution 
into the LC/tandem MS system. The HPLC conditions were already described in chapter 
II.2.4.  
For the MS monitoring a SRM different to the one described in the definitive 
method was used. C-peptide and D8-Val7,10-C-peptide were monitored in the negative 
wrong way round electrospray ionization mode (wESI-), measuring the SRM transitions at 
m/z 1509 and 1517 (precursor ions [M–2H]2- of C-peptide and D8-C-peptide) to m/z 1500 
and 1508, respectively. This SRM transition provides the same selectivity than the SRM 
transition used in the final method (from m/z 1509 and 1517 to 183.8) but is less sensitive. 
The reason for using the first transition was that at this stage of the research it was the 
best SRM known (30). For CID, argon gas at 3x10-3 mbar and a CID energy of 35 eV were 
used. The cone voltage was set to 70 V, the capillary voltage to 4.5 kV, and the source 
temperature to 175°C. 
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II.2.6. Immunoaffinity chromatography purification 
 
In a later stage of the research immunoaffinity gel was available. The technique was 
qualitatively tested as an alternative to the two-step SPE sample preparation procedure 
described in chapter II.2.4. 
 Sample preparation was carried out by a combined IAC - SPE procedure (see a 
schematic representation in Figure II.5). The IAC-gel was stored in a buffer at pH 7.4 
containing 50 mM Tris and 0.05% of sodium azide. Conditioning of the IAC columns was 
done by washing the columns with 3 mL of binding buffer (BiB; 50 mM Tris, pH 7.8 in 
water). Then, the samples were diluted 1:1 with BiB and applied to the column. 
Afterwards, the gel was washed with 5 mL of BiB, 4 mL of 10 mM ammonium acetate (pH 
4.5) and 0.2 mL of 0.1% TFA. C-peptide was subsequently eluted with 1.5 mL of 0.05% 
TFA. The IAC columns were re-equilibrated with 5 mL of BiB.  
The IAC eluate was loaded into a Sep-Pak® C18 1 cc cartridge, mounted upside 
down (see Figure III.2 in Chapter III) and previously preconditioned with 2 mL of ACN and 
2 mL of 0.1% TFA. After being loaded, the cartridge was washed with 2 mL of 0.1% TFA 
and 2 mL of 10/90/0.1 (v/v/v) ACN/water/TFA. Finally, it was mounted in the normal flow 
direction for elution with 0.25 mL of 40/60/0.1 (v/v/v) ACN/water/TFA. The extracts were 
evaporated to dryness at 50 °C with nitrogen and stored at -20 °C until analysis. Residues 
were reconstituted in 50 µL of 15/85/0.02 (v/v/v) ACN/water/TFA and 45 µL of this mixture 
were injected in the LC/tandem MS system.  
 
IAC, Sepharose
Dilute serum
Sep Pak C18 (reverse-
loading mode)
HPLC-MS analysis
wESI-, SRM 
[M-2H]2- → m/z 183.8
 
 
Figure II.5. Schematic representation of the IAC sample preparation procedure. 
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II.2.7. Optimization of the MS conditions 
 
Based on previous experience at our laboratory (27,30), TFA was selected as modifier for 
chromatography and all measurements were performed in wESI- operation mode. The 
CID experiments were carried out in the first place to find the most sensitive (yet selective) 
SRM transition and in the second place to identify the fragments formed after CID. 
 For the realization of these experiments, chromatography was performed with a 
PRP-3 column (50x2.1mm) under isocratic conditions with 22/78/0.02 (v/v/v) 
ACN/water/TFA at a flow rate of 0.2 mL/min. 
 
Selection of the most sensitive SRM transition 
In order to find the best SRM conditions for quantification, spectra of the [M-2H]2- parent 
ion were generated at different collision energies and collision gas pressures. Additionally, 
helium instead of argon as a collision gas was tested. Once the most sensitive SRM 
transitions were selected, all MS parameters were optimized to obtain maximum 
sensitivity. The S/N ratios of the different SRM transitions were calculated after injection of 
1 ng of C-peptide.  
 
CID fragmentation elucidation  
In a previous study at our laboratory a provisional fragmentation pathway for the CID of 
the doubly charged ion [M–2H]2- of C-peptide was assigned (37 and Fierens doctoral 
thesis). However, as soon as access to the labelled IS was possible, it was realized that 
this assignment was erroneous. Thus, the fragmentation mechanism was investigated in 
more depth by measuring unlabelled, labelled, Val-C-peptide and C-peptide-Val 
standards. The latter were C-peptide analogues elongated at the N-terminus and C-
terminus with valine (Val-C-peptide/C-peptide-Val; Mw 3119.4) (both from American 
Peptide Company).  
 CID-spectra of the doubly charged ion [M–2H]2- of C-peptide (m/z 1509.1), labelled 
C-peptide (m/z 1517.1), Val-C-peptide and C-peptide-Val (m/z 1558.7) were recorded. 
The scans were divided in the ranges from m/z 100–1600 and m/z 1600–3150. The 
conditions were: 3s/scan; collision gas argon at 3x10-3 mbar; CID energy 40 eV; cone 60 
V, capillary -3.5 kV, and source temperature 175 °C. Mass spectrometric resolution was 
1.5 mass units, expressed as full width at half height. Note that a better resolution could 
not be obtained without major loss of signal intensity.  
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II.2.8. Stability of standards and serum 
 
The stability of stock standard solutions was already studied (31). It was concluded that 
solutions down to 10 mg/L, containing 1% BSA and stored at -20°C were stable. As 
explained before, the concentrations of C-peptide in serum are 50 times lower than in 
urine. For this reason the working-day solutions for the preparation of calibrators have to 
be lower in concentration. Experiments were done to ensure the stability of these working 
solutions before preparing the calibrators with equivalent amount of IS. At the same time, 
the process of submitting the calibrators through analysis was tested in order to determine 
whether or not a difference would be observed. Finally, the stability of C-peptide in the 
serum samples was also addressed. 
 
Stability of the D8-Val7,10-C-peptide and validity of isotopic dilution approach 
Although the H/D exchange in D8-Val7,10-C-peptide during the extraction procedure was 
considered very improbable in view of the position of the deuterium atoms (present on the 
valine carbons and not adjacent to a functional group which may impart reactivity), it was 
investigated indirectly from a preliminary precision experiment. This experiment was done 
by analysis on six consecutive days of an aliquot of a serum pool (with a C-peptide 
concentration of ~4.0 µg/L) to which an equivalent amount of D8-Val7,10-C-peptide was 
added. After the measurements were performed the isotope ratios were calculated and 
their variation evaluated. 
 
Stability of standard working solutions and verification of calibrators through 
analysis 
The stability of C-peptide in the working solutions made in 0.09 µg/L (0.003%) of BSA was 
verified by comparing the isotope ratios of six calibration mixtures (containing unlabelled 
and labelled C-peptide) with another 6 calibration mixtures prepared from a solution 
containing 30 µg/L (1%) of BSA. Since the latter could not be directly injected into the 
LC/MS system they were taken through the complete sample pretreatment procedure. At 
the same time, this experiment validated whether it was justified to measure the 
calibration mixtures directly instead of after processing. The difference between the mean 
isotope ratios of each series was assessed for significance with a two-sided Student t-test 
(95% probability level). Note that before performing the Student t-test a F-test (95% 
probability level) has to be done to investigate if there is a significant difference between 
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the variances of the different data sets. Depending on the result, it would be opted for a 
Student t-test that supposes equal or different variances. This working method was 
followed for all Student t-tests described in the rest of this dissertation and will not be 
repeated again. 
 
Stability of C-peptide in serum 
The stability of C-peptide was tested in 9 randomly chosen samples from the stimulation 
curves. Their concentration range was from 3 µg/L to 12 µg/L. They were analyzed 6 
times in a week with the Roche Modular Analytics E170 after different storage conditions, 
i.e., at room temperature (20 to 25 °C), between 2 and 8 °C and at -20 °C. The values 
from day 2 to 6 were tested for significance of difference with those on day one in a two-
sided paired t-test (95% probability).    
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II.2.9. Method validation 
 
The two-step SPE-LC/tandem MS measurement procedure was validated. The following 
experiments and materials were employed. 
 
Specificity 
Interference by other than C-peptide analytes during LC/tandem MS measurement was 
assessed by analysis of several serum samples selected from the method comparison 
study without addition of isotopically labelled C-peptide. Any peak at the m/z values used 
for monitoring the transitions typical for D8-Val7,10-C-peptide would be interpreted as an 
interference. Interferences in the transition corresponding to C-peptide were evaluated 
from the chromatography and results of precision and accuracy at different 
concentrations. The presence of any interference would affect the precision and accuracy 
to a different extent at different concentrations. 
 
Limit of detection and quantification 
The LOD and LOQ from the ID-LC/tandem MS procedure were determined from analysis 
of 2.5 mL of serum samples of low concentration (<0.5 µg/L) and subsequent dilution until 
a S/N of 3 (LOD) and 10 (LOQ).  
 
Recovery of the sample preparation procedure 
The total recovery of our combined SPE procedure was tested with a serum pool from 
which eight aliquots were sampled on a gravimetric basis. To four of the aliquots an 
amount of non-labelled and isotopically labelled C-peptide (to obtain a 1:1 isotope ratio) 
was added (also on a gravimetric basis) before performing the SPE; to the next four 
aliquots, only non-labelled C-peptide was added before processing. Collection of the 
extracts from the Oasis® MCX cartridges was done in tubes containing an equivalent 
amount of D8-C-peptide. The recovery (in %) was calculated from the isotope ratios 
obtained for both series of four aliquots.  
 
Ion suppression 
Ion suppression was investigated by comparing the responses for the injection of a IS 
solution and the injection of a processed serum sample whose extract was redissolved 
with the same IS solution.  
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Precision 
For the estimation of the imprecision data from different experiments were used. First, the 
data from the dedicated experiments with two sera containing endogenous C-peptide 
concentrations (1.6 and 4.0 µg/L) was used. The sera were obtained from a voluntary 
blood donation after overnight fasting and 60 min after glucose stimulation. Aliquots were 
stored at -20 °C and analyzed in duplicate during 11 analytical runs. Secondly, the data 
from the two supplemented serum pools utilized for internal quality control in the method 
comparison study (concentrations 4.1 µg/L and 14.8 µg/L) was employed. Thirdly, we 
used the data from the recovery experiments (see below) performed for the estimation of 
accuracy and trueness was used. 
 The within-run and between-run CVs (%) (CVbetween, CVwithin) were calculated with 
Model II ANOVA (analysis of variance). The CVtotal was obtained from the combined 
CVbetween and CVwithin (square root of the sum of the squared CVbetween and CVwithin). The 
CVs were calculated following the Clinical and Laboratory Standards Institute (CLSI) EP5-
A2 protocol (37). 
 
Accuracy and trueness 
Accuracy and trueness were estimated from recovery studies. In these experiments, C-
peptide at three concentrations (1.9 µg/L, 4.8 µg/L and 7.8 µg/L) was added to a protease-
free BSA solution (70 g/L in 0.9% NaCl) and to a serum pool containing an endogenous 
amount of C-peptide of 1.16 µg/L. Before supplementing the BSA solution, it was verified 
first that this solution was C-peptide free. In a similar way, before supplementing the 
serum pool the base line value of C-peptide was quantified in duplicate during four 
analytical runs using the ID-LC/tandem MS methodology. The % recovery in each 
analytical run was calculated by comparing the mean value (BSA solutions) or mean 
difference between the observed and the baseline value (serum) with the amount of C-
peptide added. The range of the calculated % recoveries and the mean of that range (± 
95% confidence interval (CI)) were used as a measure of respectively the accuracy and 
the trueness. 
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II.2.10. Method comparison  
 
The two-step SPE ID-LC/tandem MS measurement procedure was applied for the quality 
assesment of three routine measurement procedures. The following strategy and 
materials were employed. 
 
Measurement strategy 
The fasting blood samples were transported to the laboratory within 30 min of withdrawal. 
The remaining samples (after glucose stimulation) were received in the laboratory within 
30 min of the last collection, after which the analysis (in duplicate) was immediately 
started with the three immunoassays. After successful measurement with the Roche 
Modular Analytics E170 (note that this immunoassay is the test system routinely used in 
the Laboratory for Hormonology of the Department of Clinical Chemistry of Ghent 
University Hospital), the remaining serum was transported ice-cooled to the MS 
laboratory. There, the samples were immediately processed. After evaporation, the 
residues were stored between 2 and 8 °C until LC/tandem MS measurement the next day. 
Three routine measurement procedures were compared with the two-step SPE-ID-
LC/tandem MS via split-sample measurement of 75 serum samples. All the 
measurements done under the routine measurement procedures were performed in the 
Laboratory for Hormonology of the Department of Clinical Chemistry at Ghent University 
Hospital. Measurement of the 15 stimulation curves by both the ID-LC/tandem MS and 
routine laboratory was done in seven analytical runs spread over four weeks, meaning 
that all curves were measured with the same batch of the immunoassays. 
Each sample was measured in singlicate with the routine measurement 
procedures. The measurements in the ID-LC/tandem MS laboratory were done once 
according to a measurement protocol with bracketing of the patient and control samples 
(maximum six) between two times three calibration mixtures, which allowed analysis of 
samples of two stimulated patients per working day. As described above, the quality of 
each analytical run was controlled from the data of two supplemented serum pools at C-
peptide concentrations of 4.1 µg/L and 14.8 µg/L.  
 
Routine measurement procedures 
The selection of the C-peptide immunoassays was done on the basis of the availability of 
the automated immunosystems in the Laboratory for Hormonology except for one RIA 
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system. The routine measurement procedures evaluated in this study were the Roche 
Diagnostics GmbH electrochemiluminescence immunoassay (ECLIA) for use on the 
Modular Analytics E170 (Basel, Switzerland); the Diagnostic Products Corporation (DPC) 
Immulite® 2000 C-peptide solid phase competitive chemiluminescent enzyme 
immunoassay (Los Angeles, CA, USA); and the Cis bio international IRMA-C-PEP 125I-
radioimmunometric assay (Santa Clara, CA, USA).  
All assays are calibrated against the WHO 1st IRP, code 84/510 (1986) from 
NIBSC (38-40). The assays have measurement and/or calibration ranges from 0.01 to 40 
µg/L (Roche), 0.5 to 7.0 µg/L (DPC) and 0.24 to 16.5 µg/L (Cis bio). The reference 
intervals quoted in the instruction sheets are: 1.1 to 4.4 µg/L (Roche; n = 96), 1.1 to 5.0 
µg/L (DPC; n = 71) and 1.1 to 3.5 µg/L (Cis bio; n = 40). All measurements were 
performed in accordance with the respective manufacturer's instructions.  
Each assay's performance was controlled either with assay specific control 
samples (for DPC the C-peptide Control Module with assigned target values of 1.0, 3.0 
and 5.1 µg/L; for Cis bio the C-peptide MYRIA-S with targets of 0.6 and 1.4 µg/L) or with 
in-house prepared serum pools targeted before at 0.5 and 5.5 µg/L. 
 
Statistical methods and graphical presentation 
The method comparison data were investigated by Deming regression analysis (CBstat 
software version 5.1 from K. Linnet, Risskov, Denmark) and by difference plots with 
integrated analytical quality specifications. Analytical quality specifications derived from 
the total expected imprecision of each method pair (CVmp; see Formula II.1) and a total 
error (TE) specification derived from the biological variation of C-peptide were used. The 
total biological error (TEspecification) was corrected for the imprecision of the RMP (formula 
II.2). 
 
n
CV
n
CVCV
2
assay
2
MS
mp +=  
 
Formula II.1. CV of the method pair. Note that n is the number of repeated measurements of the same sample 
with each method. 
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Formula II.2. Calculation of a new specification that accounts for the imprecision of the RMP (CVRMP) in the 
method comparison. 
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II.3. RESULTS AND DISCUSSION 
 
II.3.1. Sample preparation procedure  
 
Existing procedures for sample preparation, i.e., SPE with Sep-Pak® C18 cartridges, 
described by Kippen et al. and Darby et al. (2, 25), were used as a starting point for our 
sample preparation procedure. A procedure based on IAC purification was also developed 
in a later stage of this dissertation. 
  
Comparison with other procedures described in the literature 
As documented in Figures II.6.C to F, the combination of the sample pretreatment 
procedures from Kippen et al. and Darby et al. (adapted for practical reasons, see 
paragraph II.2.5) with our LC/tandem MS measurement conditions did not result in 
sufficient purification for a sensitive and specific LC/tandem MS measurement in a 
reasonable time and without damage of the chromatographic column (measured in terms 
of increase of column pressure). Therefore, a new procedure consisting on the 
combination of two SPE procedures was developed, i.e., an equivalent of the Darby C18 
method (25) followed by a mixed reverse phase-cation exchange sorbent (Oasis MCX). 
Our C18 SPE procedure differs from the original one in that the cartridges are loaded 
twice with the diluted serum sample and eluted with 1.5 mL of 50% instead of 40% ACN in 
order to not compromise the recovery.  
Note that different deproteinization techniques prior to SPE with Sep-Pak® C18 
were also tested, more specifically deproteinization was tested with: hydrochloric acid, 
acetonitrile, ammonium sulfate, and ultrafiltration. However, none of them gave an 
advantage over the “in situ deproteinization” during Sep-Pak® C18 clean up (data not 
shown). 
The developed sample preparation procedure is superior in several aspects. The 
reconstructed ion chromatograms shown in Figure II.6.A and B give evidence of sufficient 
sample purification. Interference-free ion chromatograms with a stable baseline are 
obtained. It must also be noted that, after injection of reconstituted serum extracts 
obtained by the method of Darby et al. (25), the column back-pressure tended to increase, 
even after centrifugation at 5000 rpm for 5 min. We suppose that this was due to an 
incomplete dissolution of the extraction residue upon reconstitution. Also in terms of 
sample throughput, our procedure with a gradient of only 5 min and a total run time of 11 
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min was superior to the other methods. For example, in the method of Kippen et al. (2), 
purification step was needed with a Nucleosil C18 microbore  column (1x150 mm) eluted 
with a 60 min gradient program before direct infusion into the ESI-MS system. In the 
method of Darby et al., (25) the elution from the Vydac C18 column (2.1x150 mm) was 
done with a 10 min gradient. Note that for the alternative methods only the gradient elution 
time can be reported, since the total HPLC run time is not mentioned in any of the 
references. 
 
 
 
Figure II.6. Ion chromatograms of C-peptide (A, C, E) and its deuterated analogue (B, D, F) obtained by 
LC/tandem MS analysis (wESI-; SRM from m/z 1509 to 1500 and from m/z 1517 to 1508, respectively) of 2.5 
mL of serum processed according to three sample pretreatment procedures. The serum pool had an 
approximate C-peptide concentration of 0.6 µg/L. The ion chromatograms shown in (A) and (B) were obtained 
after processing of the serum sample with our two-step SPE sample purification procedure; those shown in 
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(C) and (D) with the method of Kippen et al. (2) and those shown in (E) and (F) with the procedure of Darby et 
al. (25). The arrows in (C) to (F) indicate the position of the signals of C-peptide and the deuterated analogue. 
Note that all chromatograms have the same scale and respect the ratio of the absolute abundances of the 
peaks. 
 
Immunoaffinity chromatography 
In a later phase of the research, a sample preparation procedure based on IAC was 
tested. Also IAC resulted in interference free chromatograms (Figure II.7). This method is 
an interesting alternative to our previously described two-step SPE procedure. A major 
disadvantage of IAC is that the columns have to be reused due to their high cost. This 
increases the risk of cross contamination and loss of purification efficiency. Long term 
experience is needed to investigate whether these potential problems occur with the gel 
used. 
 
 
 
 
 
 
 
  
 
Figure II.7. Reconstructed chromatograms for a sample of 1 mL containing 2.5 ng of C-peptide (left) and 
deuterated analog (right) purified with IAC and measured by LC/tandem MS analysis (wESI-; SRM from m/z 
1509 to 183.8 and m/z 1517 to 183.8, respectively). 
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II.3.2. Optimization of the MS conditions 
 
The experience at our laboratory with C-peptide was that HPLC with TFA and MS in the 
wESI- mode gave the best results in terms of combining chromatography and MS 
performance. In this way the advantages of TFA for peptide chromatography with 
exceptional MS sensitivity are combined. The MS1 spectrum of C-peptide in the wESI- 
mode is shown in Figure II.8. The spectrum is dominated by the doubly negatively 
charged ion, i.e., the [M-2H]2- which carries almost the complete ionization. This is 
exceptional MS behavior for quantitative purposes. In consideration of the above, the 
efforts were focused on optimizing the CID conditions of this ion in order to obtain the 
most sensitive SRM transition.  
 
 
 
 
 
Figure II.8. wESI- spectrum of C-peptide. 
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Selection of the most sensitive SRM transition 
Fierens et al. (37) used high mass range fragments for quantification of C-peptide. Those 
are most intense at low CID energies (Figure II.9). Our investigations were focused on the 
low-mass fragment ions generated with high CID energies (see Figure II.10). The most 
promising ions for SRM were m/z 183.8, 345.4, and 483.5.  
 
 
 
 
Figure II.9. CID spectrum of the [M–2H]2- ion of C-peptide obtained at a CID energy of 40 eV. Only the range 
from m/z 100–1600 is shown because no significant ions were observed at m/z values higher than 1600. 
 
 
 
 
 
Figure II.10. CID spectrum of the [M–2H]2- ion of C-peptide obtained at a CID energy of 80 eV. 
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From those, the fragment ion with m/z 183.8 gave the best S/N ratios. Table II.3 compares 
the S/N ratios obtained by the low- and high-mass SRM transitions for a typical serum 
sample. The S/N ratio of SRM transition from m/z 1509 to 183.8 was a factor two better 
than those of the high-mass transitions. All three transitions had similar selectivity. 
 
Table II.3. MS optimized conditions and S/N values for different SRM. See corresponding chromatograms in 
Figure II.11. 
 
m/z SRM Cone (eV) Collision energy (eV) 
Skimmer lens 
offset S/N 
1509 → 1500 82 40 13 25 
1509 → 1327 80 40 14 20 
1509 → 183.8 85 78 12 45 
 
 
 
 
 
 
Figure II.11. Chromatograms corresponding to the measurement of 1 mL of serum with a concentration of 1.4 
µg/L (the peak represents an absolute amount of 1 ng on column) obtained by monitoring of different SRM: (A) 
from m/z 1509 to 1500; (B) from m/z 1509 to 1327; (C) from m/z 1509 to 183.8. 
S/N = 25 
S/N = 20 
S/N = 45 
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CID fragmentation elucidation  
The backbone fragmentation nomenclature for positive ions (41) was not used (see Figure 
II.12), instead the one proposed for negative ions by Bowie (42) and schematically 
presented in Figure II.13. The reason for that choice is that many backbone cleavage 
anions have no corresponding positive analogues and consequently the nomenclature for 
positive ions is not appropriate. Note that the scheme from Figure II.13 shows only where 
the molecule splits, given that the final fragment ion is often formed by complex 
mechanisms that include neutral loss of hydrogen as well as proton loss. As in the positive 
ion mode, there are many different backbone cleavages in negative ion spectra. Although 
two of these, α and β, provide data equivalent to those of B and Y+2 positive ion 
cleavages, the mechanisms of formation of the negative ions are quite different from those 
of their positive ion counterparts. There are also other fragmentations possible in the 
negative mode (ε, β’, …), however, they will not be mentioned because they do not apply 
to the C-peptide molecule. A detailed explanation of the negative ion cleavages that take 
place is beyond the scope of this dissertation. For further information, the reader is 
referred to the review by Bowie’s group (42). 
 
H2N-CHR1-CO-NH-CHR2-A|
X
-CO-B|
Y
-NH-C|
Z
-CHR3-CO2H 
 
Figure II.12. Backbone fragmentation nomenclature for positive ions. 
 
H2N-CHR1-CO-NH-CHR2-(-)|
(-)
-CO-β|
α
-NH-δ|
γ
-CHR3-CO2H 
 
Figure II.13. Backbone fragmentation for negative ions. Note that the fragmentation “-“ is absent in the 
negative mode. 
 
In Figures II.9 and II.10 the main CID fragment ions of the [M-2H]2- ion of C-
peptide can be seen. A summary of the m/z values and fragment assignment for the four 
molecules studied (C-peptide, (D8-Val7,10)-C-peptide, Val-C-peptide and C-peptide-Val) is 
presented in Table II.4. The CID spectrum of C-peptide is characterized by two abundant 
ion series at m/z below 1509.1 (m/z 1500.1, 1491.1, etc.) and around m/z 1327.0 (m/z 
1344.5, 1336.0, 1327.0, 1318.0, 1312.0) and some minor fragment ions in the mass range 
m/z 320-520 (327.3, 345.3, 443.4, 483.5, 513.6). At higher CID energies the low mass 
ions m/z 183.8, 345.4, and 483.5 are most prominent. Comparison with the data from Val-
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C-peptide and C-peptide-Val (Table II.4) shows that the higher mass series are doubly 
charged ions (expected difference 49.6 Th), while the lower mass fragments are singly 
charged ones (expected difference 99.1 Th). From the spectra of the homologues it could 
be inferred that the ion series at m/z below 1509.1 do not correspond with a backbone 
cleavage but with multiple loss of water. 
In addition, the spectra show that the ion series around m/z 1327.0 and at m/z 
513.6 and 483.5 are attributable to the C-terminus (α or γ type; no mass difference for 
Val-C-peptide), whereas the ions at m/z 443.4, 345.3 and 327.3 come from the N-
terminus (β or δ type; no mass difference for C-peptide-Val). The data for the deuterated 
C-peptide confirm these findings. The Asp residue in position 4 (D4) dominates the 
backbone cleavages (42), leading to the series of doubly charged fragment ions around 
m/z 1327.0 and to the singly charged fragment ions at m/z 345.3 and 327.3 (see Table 1 
for possible mechanisms). The other backbone cleavages occur between D4/L5 and 
L26/E27 (see Table II.4 for details). Major side-chain cleavages are observed due to the 
presence of 1 D/4 E (loss of H2O), 4 Q (loss of NH3), and 2 S (loss of CH2O) (42). 
The transitions from m/z 1509 and 1517 to m/z 1500 and 1508 corresponding to a 
loss of H2O from side-chain cleavages, are typical in peptides containing Asp and Glu 
residues and produce some of the most abundant ions in the negative ion spectra. In an 
initial stage of the method development these transitions were selected for measurement 
because they provided a good specificity and S/N ratio for quantification of C-peptide in 
serum samples. 
The generation of the fragment ion at m/z 183.8 was also investigated by 
measurement of unlabelled, labeled, Val-C-peptide and C-peptide-Val. All four 
compounds gave very similar spectra indicating that the ion at m/z 183.8 is not generated 
by the known fragmentation mechanisms involving the cleavage of a single backbone 
bond. 
 Formalistically, the ion m/z 183.8 corresponds to a {[-NH-CH2-CO-NH-
CH(C3H6NO)-CO]-[H]}- fragment of the amino acids G and Q (G and Q are adjacent to 
each other in positions 8 and 9). This ion could be generated by cleavage of two 
backbone bonds. However, to the best of our knowledge, fragmentation mechanisms for 
negative peptide fragment ions under "high" collision energies (for quadrupole mass 
spectrometers) have not been investigated yet. Therefore, the assignment of m/z 183.8 
must remain a speculation. Further investigation (e.g. high resolution measurements) was 
beyond the scope of the thesis. 
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Table II.4. Negative fragment ions obtained from the [M-2H]2- precursor ion of the different C-peptide 
molecules studied (the backbone cleavages are indicated below). 
 
C-peptide V-C-peptide 
C- 
peptide-V 
(D8-V7,10)- 
C-peptide Fragment assignment 
a Charge 
1509.1b 1558.7 1558.7 1517.1 [M-2H]2- precursor ion -2 
1500.1 1549.7 1549.7 1508.1 -H2O -2 
1491.1 1540.7 1540.7 1499.1 -2H2O -2 
1344.5 1344.5 1394.1 1352.5 α between E3 and D4 -2 
1336.0 1336.0 1385.5 1344.0 γ at D4 or α between E3 and D4-NH3 -2 
1327.0 1327.0 1376.5 1335.0 
γ at D4-H2O 
or α between E3 and D4-NH3-H2O -2 
1318.0 1318.0 1367.5 1326.0 
γ at D4-2H2O 
or α between E3 and D4-NH3-2H2O -2 
1312.0 1312.0 1361.5 1320.0 
γ at D4-H2O-CH2O 
or α between E3 and D4-NH3-H2O-CH2O -2 
513.6 513.6 612.7 513.6 α between L26 and E27-H2O -1 
483.5 483.5 582.7 483.5 α between L26 and E27-H2O-CH2O -1 
443.4 542.5 443.4 443.4 β between D4 and L5 -1 
345.3 444.5 345.3 345.3 δ at D4 -1 
327.3 426.4 327.3 327.3 δ at D4-H2O -1 
183.8 183.8 183.8 183.8 
{[-NH-CH2-CO-NH-CH(C3H6NO)-CO] -
[H]}- fragment of G8 and Q9 -1 
 
a
 E1AE3|D4|L5QVG8Q9VELGGGPGAGSLQPLAL26|E27GSLQ31 
b
 For better comparison, the theoretical m/z values are listed. All observed masses were within ±0.3 u of the 
theoretical values.  
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II.3.3. Stability of standards and serum 
 
Stability of D8-Val7,10-C-peptide and validity of isotopic dilution approach 
The coefficient of variation of 4.3% obtained for the isotope ratios during the preliminary 
precision experiment was able to confirm that there was no significant H/D exchange, if 
any. This proves the identical behavior (stability) of C-peptide and the deuterated analog 
and, as a consequence, the validity of the isotope dilution approach. In addition, the 
internal validation data in terms of precision, accuracy and trueness (see Chapter II.3.5 
and Table II.7 below) and the agreement between isotope ratios of calibration mixtures 
measured directly and after passing through analysis (see next paragraph) document the 
advantages of the ID principle. The ID approach ensures, throughout the entire procedure, 
compensation for eventual losses, degradation or incomplete recovery of C-peptide. This 
is a condition sine qua non to claim that a measurement procedure is of a higher 
hierarchical order. 
 
Stability of standard working solutions and verification of calibrators through 
analysis 
The data of the calibrators prepared from standard solutions containing 1% BSA and 
taken through the entire sample preparation procedure and the standards prepared in 
0.003% BSA and directly measured are shown in Table II.5. Statistical testing of the 
variances and means of the isotope ratios obtained for the two series of calibration 
mixtures did not reveal a significant difference (P 0.63 in the F-test and P 0.92 in the t-
test). It can be concluded that the working standard solutions prepared on the day of 
analysis are stable and that there is no need for taking the standards through analysis. 
 
Stability of C-peptide in serum 
The data of the samples stored at room temperature (20 to 25 °C), between 2 and 8 °C 
and at -20 °C and analyzed in six consecutive days is presented in Table II.6. In Figure 
II.12 the average concentration (%) for each day is plotted. The paired t-test on the data 
for the stability testing upon storage revealed a significant difference versus the reference 
from day two on for samples stored at room temperature. The concentrations decreased 
in average by 5% (day two) to 20% (day six). For the other storage conditions the 
differences were not significant (P > 0.05). The results from the stability testing prove that 
the storage conditions in our study were satisfactory to preserve the stability of C-peptide 
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Table II.5. Results of the experiment to determine the stability of the working standards and calibration 
solutions. 
 
 Standards in 1% BSA taken through analysis 
Weight ratio (C-peptide/IS) 1.0333 1.0246 0.9828 0.9998 0.9465 0.9580 
Area ratio (C-peptide/IS) 1.0272 0.9758 0.9740 0.9817 0.9114 1.0409 
Normalized (Area ratio/weigh ratio) 0.9941 0.9524 0.9911 0.9818 0.9629 1.0866 
Mean ± 95% CI 0.9948 ± 0.0550  
 Standards in 0.003% BSA directly injected 
Weight ratio (C-peptide/IS) 0.9915 0.9859 0.9879 1.0195 1.0472 1.0276 
Area ratio (C-peptide/IS) 1.0006 0.9839 1.0067 0.9930 1.0775 0.9503 
Normalized (Area ratio/weigh ratio) 1.0092 0.9980 1.0190 0.9740 1.0289 0.9248 
Mean ± 95% CI 0.9923 ± 0.0438 
 
 
in serum. In addition, they evidence that storage of the samples at -20 °C, necessary for 
logistic reasons during split-sample comparison will not jeopardize the standardization 
process. This is a comforting observation since the susceptibility of C-peptide to cleavage 
by proteolytic enzymes has always been considered a potential pitfall in standardization 
programs (9, 21). 
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Figure II.12. Average concentration (%) for samples kept at different temperatures during 6 days with the 
correspondent 95% CI. 
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Table II.6. Stability results (µg/L) for selected serum samples kept at different temperatures during 6 days. 
 
Sample Conditions Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 
20-25 °C 3.43 3.31 3.20 3.16 3.06 2.95 
2-8 °C 3.43 3.44 3.45 3.47 3.49 3.57 1 
-20 °C 3.43 3.47 3.46 3.44 3.51 3.56 
20-25 °C 6.79 6.33 6.07 5.86 5.69 5.25 
2-8 °C 6.79 6.92 6.77 6.78 6.92 6.66 2 
-20 °C 6.79 6.84 6.89 6.89 6.88 6.85 
20-25 °C 7.50 7.01 6.71 6.51 6.39 5.84 
2-8 °C 7.50 7.42 7.4 7.38 7.6 7.51 3 
-20 °C 7.50 7.52 7.57 7.53 7.47 7.35 
20-25 °C 9.17 8.78 8.53 8.31 8.20 7.34 
2-8 °C 9.17 9.24 9.21 9.23 9.29 9.15 4 
-20 °C 9.17 9.37 9.25 9.35 9.33 9.50 
20-25 °C 11.34 10.65 10.20 9.63 9.56 8.66 
2-8 °C 11.34 11.56 11.44 11.35 11.32 11.27 5 
-20 °C 11.34 11.59 11.54 11.50 11.78 11.46 
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II.3.4. Method validation  
 
Specificity 
There was no indication of ion suppression or interference by analytes other than C-
peptide or D8-Val7,10-C-peptide during LC/tandem MS measurements. The serum extracts 
without added D8-Val7,10-C-peptide and monitored at the m/z value typical for the transition 
of the isotopically labeled analogue did not show any peak between 3 and 6 min (see 
Figure II.13), except from the overlap around 5% in the SRM from m/z 1509 to 183.8. This 
overlap is taken into account in the calculation of sample concentrations. Note that this 
overlap was also present in the injections of standard solution. From the very clean 
chromatograms and the good results of precision at different concentrations, it can be 
concluded that the chances for interference are very low. 
 
   
   
   
 
Figure II.13. Chromatograms for the standard solution (on the left) and samples (on the right) measured at 
different SRM, note that no IS was added. 
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Limit of detection and quantification 
The analysis of 2.5 mL of a sample with a concentration of 0.4 µg/L resulted in a 
chromatogram with a S/N ratio of 32 (see Figure II.14). Extracts of the same sample were 
diluted before injection until S/N ratios of 10 and 3 were obtained (data not shown). 
The LOD and LOQ of the ID-LC/tandem MS procedure were estimated to be 0.03 µg/L 
(S/N ratio of 3) and 0.15 µg/L (S/N ratio of 10), respectively when processing 2.5 mL of 
serum. This was considered sufficient for reliable quantification of physiological C-peptide 
concentrations in serum (typically between ~1 and 4 µg/L). 
 
 
 
 
 
Figure II.14. Chromatogram of a processed sample of 2.5 mL containing 0.4 µg/L. 
 
 
Recovery of the sample preparation procedure 
With regard to the total recovery, no significant decrease in our sample pretreatment 
procedure as opposed to that of the Kippen et al. was observed, i.e., 77±0.8% (SEM; n=4) 
vs. 80% (2). Note that Darby et al.(25) do not specify the recovery.  
 
 
 
 
 
 
 
 
 
 
S/N = 32 
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Ion suppression 
The response for the injection of a IS solution and the injection of a processed serum 
sample whose extract was redissolved with the same IS solution were compared. Both 
gave similar intensities (see Figure II.15) (n=3), indicating the absence of ion suppression. 
 
 
 
 
 
Figure II.15. The left chromatogram represents 3 ng of an IS solution. The right chromatogram represents a 
serum extract reconstituted with an IS solution containing 3 ng. Note that the small peak at the m/z value of C-
peptide after injection of the IS is due to the spectral overlap of the IS on the ion of the standard. 
 
Precision 
The data for the precision of the ID-LC/tandem MS procedure is summarized in Table II.7. 
The CVwithin ranged from 1 to 3.5%, the CVbetween from 0.1 to 2.5%, and the CVtotal from 1.8 
to 3.8%. In general, the data demonstrates that the method is capable of reaching the 
predefined imprecision goal of a CVtotal of 3%. 
 
Accuracy and trueness 
The data for the accuracy and trueness of the ID-LC/tandem MS is summarized in Table 
II.7. The accuracy ranged between 94.6% and 104.1%, and the minimum trueness was 
98.1% (95% CI, 96.2%–100.0%). These data indicate that the method fulfills the 
predefined trueness goal of 5%. 
Note, however, that the trueness of the method relies on the manufacturer 
certificate for what concerns the purity of the standard and the filling weight. If an 
international standardization of C-peptide measurements is considered, a certified primary 
reference material needs to be developed. Unfortunately, the WHO standard IRP 84/150 
cannot be considered as such a material because the ampoule content and the purity of 
that material are insufficiently characterized. 
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Table II.7. Precision, accuracy and trueness of the ID-LC/tandem MS procedure. 
 
 
 CVwithin, % CVbetween, % CVtotal, % Accuracy, % Trueness (95% CI), % 
Dedicated seraa     
1.6 µg/L (n = 11)b 1.6 2.5 2.9 - - 
4.0 µg/L (n = 11) 2.1 1.7 2.7 - - 
Internal quality control materialsc     
4.1 µg/L (n = 16) 3.5 1.3 3.7 - - 
14.8 µg/L (n = 12) 3.5 1.3 3.8 - - 
Albumin solutions  (n = 5)     
1.9 µg/L 1.6 0.8 1.8 96.7 - 99.8 98.1 (96.2-100.0) 
4.8 µg/L  1.9 0.1 1.9 97.6 - 101.0 99.8 (98.1-101.5) 
7.8 µg/L  1.0 1.6 1.8 97.6 - 102.8 100.0 (97.2-102.8) 
Supplemented serad (n = 5)     
1.9 µg/L 1.3 1.5 2.0 94.6 - 104.1 98.1 (95.3-100.9) 
4.9 µg/L 2.1 0.6 2.2 98.3 - 103.8 100.2 (97.6-102.8) 
7.8 µg/L 1.7 1.4 2.3 97.1 - 103.6 99.5 (96.1-102.9) 
 
aMean endogenous serum C-peptide concentration. 
bNumber of analytical runs in which a sample was assayed in duplicate. 
cMean C-peptide concentration in a supplemented serum pool. 
dThe basal C-peptide concentration was 1.16 (95% CI, 1.11-1.21 µg/L) µg/L (n = 4). 
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II.3.5. Method comparison 
 
The two-step SPE-ID-LC/tandem MS measurement procedure was applied to the 
evaluation of three routine immunoassays. The results of the method comparison study 
are presented in the form of i) scatter plots with Deming regression (Figure II.16), ii) 
absolute and % difference plots before and after recalibration (Figure II.16 to 19). 
 
Data before recalibration 
With ID-LC/tandem MS, the basal C-peptide concentrations in the 15 patient samples 
ranged from 0.5 to 3.7 µg/L; the stimulated concentrations ranged from 1.2 to 9.5 µg/L. 
The Deming regression analysis (see also Table II.8) indicated that the commercial 
assays considerably overestimated the C-peptide concentrations in a proportional way 
(slopes significantly >1) and to a different extent (slopes: Cis bio = 1.90; Roche = 1.74; 
DPC = 1.53). In addition, a statistically significant negative intercept for the Cis bio assay 
was documented. This interassay discrepancy documents the fact that calibration with a 
common calibrator (IRP 84/510) did not provide comparability of the measurements. On 
the other hand, all immunoassays showed excellent correlation coefficients (Roche, r = 
0.9914; Cis bio, r = 0.9889; DPC, r = 0.9815) and low standard errors of the estimates 
(Sy/x = 0.46–0.59 µg/L). The magnitude of Sy/x is nearly entirely the result of the 
combined imprecision of the immunoassay and the ID-LC/tandem MS measurement 
procedure. This is in contrast to the suggested differences in specificity of different 
antisera (21). The high correlation coefficients and low Sy/x values are a good basis for 
recalibration of the investigated immunoassays by use of the regression equations of the 
method comparison. The outcome of a recalibration based on the method comparison 
data is outlined below. 
 
Table II.8. Deming regression data of the different immunoassays compared with ID-LC/tandem MS. 
 
 Slope (95% CI) Intercept (95% CI) (µg/L) 
Sy/x 
(µg/L) 
Correlation 
coefficient (r) 
Roche 1.74 (1.695 - 1.786) -0.15 (-0.348 - 0.056) 0.461 0.9914 
DPC 1.53 (1.468 - 1.600) -0.016 (-0.313 - 0.281) 0.585 0.9815 
Cis bio 1.90 (1.837 - 1.959) -0.90 (-1.18 - -0.626) 0.570 0.9889 
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Figure II.16. Method comparison between three immunoassays and the ID-LC/tandem MS measurement 
procedure. For each immunoassay the scatter and absolute difference plot is shown. Scatter plots show also 
the curve from Deming regression analysis and the x = y line.  
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Data after recalibration 
Comparing Figure II.17 A and B with C and D shows that the immunoassays can 
successfully be recalibrated by the outcome of the method comparison study. The 
residual spread of the data is only an effect of the within-assay deviations from the ID-
LC/tandem MS method. 
 
 
 
Figure II.17. Combined scatter and absolute difference plots before (A and B) and after (C and D) recalibration 
with the respective weighted Deming equations. 
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Recalibrated data and expected total variation 
For a more detailed investigation of the residual spread of the data after recalibration, the 
% difference plots after recalibration shall be used (Figure II. 18). This Figure also 
includes the expected spread of the data if only the imprecision of the respective method 
pairs is considered (see also Table II.9).  
 
Table II.9. Total imprecision corresponding to each method, to the method pair and 95% expected interval for 
the method comparison results. 
 
 CVtotal CVmp 1.96 x CVmp 
MS 3.8 - - 
Roche 2.3 4.5 8.8 
DPC 8.8 9.6 18.8 
Cis Bio 6.6 7.6 14.9 
 
 
The investigation of the plots shows that somewhat more than the expected 5% of 
the data fall out of limits that represent 1.96 X CVmp. However, it requires only a slight 
expansion of the limits to observe only 5% of the values outside the limits. This confirms 
the prior expressed statement that the main contribution to the variability around the 
regression line comes from the combined imprecision of both the field immunoassay and 
ID-LC/tandem MS. Sample related effects play only a minor role.  
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Figure II.18. Percentage difference plots after recalibration for each individual immunoassay. The dotted lines 
represent the 95% expected interval (1.96xCVmp). 
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Recalibrated data and total error limits derived from biology 
Additionally, the outcome of recalibration shall be investigated in light of an objective 
quality goal for total error. Such a goal can be derived from the biological variation of C-
peptide: TE = 0.25 CVBetween + 1.65 x [0.5 x CVWithin] = 11.7%. However, this goal applies 
only to a situation where the RMP is error-free. In our application, we have to adjust the 
TE by the imprecision of the RMP as calculated in Materials and Methods, which results in 
a TE value of 14%. This value is shown in the % difference plots after recalibration in 
Figure II. 19. Inspection of the figure indicates that the Roche and the CIS bio methods 
may be able to achieve the total error goal of 14 % (roughly 5% of the data out of the 
limit), while the DPC method may not fulfill the limit (considerably more than 5% of the 
data outside the limit). 
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Figure II.19. Percentage difference plots after recalibration for each individual immunoassay. The dotted lines 
represent the corrected TE specification of 14% that results from the combined biological variation (11.7%) 
and the imprecision of the ID-LC/tandem MS method.
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II.4. CONCLUSION 
 
We developed and validated an ID-LC/tandem MS procedure with a sufficient LOD/LOQ 
and specificity for interference-free measurement of basal and stimulated serum C-
peptide concentrations. The internal validation data documented the compensating effects 
of ID for eventual losses, degradation, or incomplete recovery of C-peptide, which is 
necessary for a RMP. The procedure had reasonable recovery and short run time. 
We reached this by combining ID-MS with a two-steps SPE procedure of serum 
(43) and applying negative electrospray ionization and high energy CID of the doubly 
charged deprotonated C-peptide/D8-Val7,10-C-peptide molecule [M-2H]2- from m/z 1509.2 
to 183.8 and 1517.1 to 183.8, respectively. The existing sample pretreatment procedures 
prior to analysis of C-peptide in serum with ID-LC/tandem MS were improved.  
We were able to elucidate the fragmentation pathway of C-peptide with ESI- and 
CID monitoring of the doubly charged deprotonated molecule [M–2H]2-. For example, 
backbone fragmentation is dominated at the Asp site and losses of water from side-chain 
cleavages of Asp and Glu residues occur.  
The method was successfully applied to a method comparison study with three 
immunoassays. The comparison showed the need of standardization of C-peptide 
measurements. It was demonstrated that standardization could be achieved on the basis 
of a method comparison study such as has been described in this dissertation.  
It should be noted, however, that the presented ID-LC/tandem MS measurement 
procedure does not yet have the status of a SI-traceable RMP. To this end, it will be 
necessary to develop an internationally accepted primary calibrator that is certified in 
terms of mass units. Note that the WHO IRP 84/510 does not meet this criterion, since the 
ampoule content was only nominally assigned the value of 10 µg by comparison with 
several commercial C-peptide preparations. Additionally, the ID-LC/tandem MS 
measurement procedure should, as part of an external validation process, be challenged 
in round-robin trials with other laboratories performing the same or a variant of the ID-MS 
measurement procedure in order to assess a sufficient level of interlaboratory agreement. 
Finally, it should be nominated for identification by an authoritative organization such as 
the recently established JCTLM (44).  
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CHAPTER III. 
 
DEVELOPMENT AND APPLICATION OF A 
REFERENCE MEASUREMENT PROCEDURE FOR 
INSULIN IN SERUM 
___________________________________________ 
 
 
The development of the ID-LC/tandem MS measurement procedure for serum insulin was 
published in: 
 
- Van Uytfanghe K, Rodríguez-Cabaleiro D, Stöckl D, Thienpont LM. New liquid 
chromatography/electrospray ionization tandem mass spectrometry measurement 
procedure for quantitative analysis of human insulin in serum. Rapid Commun Mass 
Spectrom 2007;21:819-21. 
 
 
The validation of the ID-LC/tandem MS measurement procedure for serum insulin and 
investigation of the method feasibility for the purpose of standardization by performing a 
method-comparison study with four immunoassays was published in: 
 
- Rodríguez-Cabaleiro D, Van Uytfanghe K, Stove V, Fiers T, Thienpont LM. Pilot study 
for the standardization of insulin immunoassays with isotope-dilution liquid 
chromatography-tandem mass spectrometry. Clin Chem 2007;53 (in press). 
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III.1. INTRODUCTION 
 
III.1.1. Insulin measurements in the clinical laboratory 
 
In the clinical laboratory, measurements of insulin are performed with a great 
variety of immunoassays (1). However, the quality of these assays has long been a matter 
of concern. The problems encountered are lack of standardization, non-specificity of the 
used antibodies and/or the presence of anti-insulin antibodies and insulin auto-antibodies 
in the patients samples (1, 2). For example, the ADA task force on standardization of 
insulin assays reported widely disparate results from immunoassays (2). Problems with 
insulin immunoassays have been confirmed recently (3, 4). These problems hinder efforts 
towards achieving consistent measures for treatment guidelines. To address this issue, 
the ADA in conjunction with the NIDDK and the Centers for Disease Control and 
Prevention (CDC) convened an international work group in 2004 to evaluate the specificity 
of different assays, to establish guidelines for assay acceptability, and to develop a 
standardization program to achieve uniform, accuracy-based values. A recent report on 
the progress made by the work group concluded that "a common insulin reference 
preparation did not change the among-assay CV and failed to improve harmonization of 
results among assays" and that the "investigation of a RMP for insulin should be a priority 
to provide a metrologically appropriate basis to evaluate the accuracy of routine methods" 
(3). Similarly, a European group stated in a recent report that "a reference method for 
measurement of insulin is required with an international standard defined in terms of 
mass" (4). This publication evoked an editorial with the title “Insulin immunoassays: fast 
approaching 50 years of existence and still calling for standardization” (5). Altogether, this 
shows the urgency and timeliness for the development of a RMP for serum insulin. 
 
III.1.2. Instrumental analytical measurement procedures for insulin 
  
A variety of HPLC-based measurement procedures for insulin have been described for 
pharmaceutical or research applications (6-15) and for the analysis of insulin in biological 
matrices (16-23). However, only a few methods for the analysis of insulin in serum have 
been described that are based on LC-MS (24-27). An overview of these methods can be 
found in Table III.1. Note that only the procedure from Kippen et al. (24) has enough 
sensitivity to measure endogenous low-level insulin (reference interval of 0.07-0.87 µg/L 
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(= 12-150 pmol/L or 1.7-22 mIU/L)) (28) and makes use of an isotopically labeled IS. 
However, a disadvantage of the procedure from Kippen et al. is the off-line sample 
preparation with a 60 min gradient and MS sample introduction via infusion.  
 
Table III.1. Overview of the LC/MS procedures for insulin in serum described in the literature. 
 
Author 
(reference) IS 
Sample 
preparation 
HPLC MS 
LODa 
(fmol) 
Kippen AD 
et al. (24) 
 
[2H16] 
insulin 
Sep-Pak® C18 
SPE 
or 
IAC + Sep-Pak® 
C18 light SPE 
Nucleosil C18 (150x1 mm) 
 
60 min gradient with 
ACN/water/0.1% TFA 
Off-line 
Micromass VG 
single quadTM 
ESI+ 
 
Short scan 
m/z 1159-1168 
[M+4H]4+ 
< 3 
Darby SM 
et al. (25) no 
Sep-Pak® C18 
SPE 
Hesperia Vydac C18 
(150x2.1 mm) 
 
10 min gradient with 
ACN/water/0.04% TFA 
Finnigan MAT 
LCQTM Qtrap ESI+ 
 
SIM 
m/z 1453 and 
1936 
172 
Hunter SJ 
et al. (26) no 
Sep-Pak® C18 
SPE 
Vydac C8 (250x4.6 mm) 
 
35 min gradient 
ACN /water/0.1% TFA 
Off-line 
Finnigan MAT 
LCQTM Qtrap ESI+ 
 
Scan 
m/z 300 – 2000 
[M+3H]3+ 
- 
Thevis M et 
al. (2005) 
(27) 
Bovine 
insulin 
IAC + Oasis® 
HLB SPE 
Agilent Zorbax 300SB-C18 
(50x1 mm), 5 µm 
 
Gradient with ACN 
/water/0.5% acetic 
acid/0.01% TFA 
Applied 
Biosystems 
QTrapTM ESI+ 
 
Product ion scan 
m/z 1163 to 100-
1200 
155 
 
a Absolute amount of insulin injected in the system. 
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III.1.3. Objectives 
 
The objective was the development of an ID-LC/tandem MS measurement procedure for 
serum insulin and its application for the evaluation and standardization of insulin 
immunoassays. The method development focused on the following topics: 
 
- Standardization 
The stabilization effects of glycerol, albumin, glargine and insulin-depleted serum were 
investigated. The link between our standard and the WHO insulin 1st IRP 66/304 was 
investigated. 
 
- Sensitive mass spectrometric detection 
CID experiments were performed with different gases on two different LC-tandem MS 
configurations. 
 
- Effective sample purification 
Two approaches were studied: a double stage SPE procedure and an IAC method. 
 
- Validation of the finally selected ID-LC/tandem MS procedure 
Finally, the feasibility of the method for the purpose of standardization was tested by 
performing a method comparison study with four representative commercial assays. 
 
Note that the method development has been done in cooperation with K. Van 
Uytfanghe. 
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III.2. MATERIALS AND METHODS 
 
III.2.1. Specifications and requirements for a serum insulin candidate RMP 
 
The ADA work group proposed the following performance specifications for such a 
procedure: a LOQ of 0.07 µg/L (= 12 pmol/L or 1.7 mIU/L), a CVtotal of maximum 3% (6 – 
7% at the LOQ), and a bias limit of ±5% (29).  
 
III.2.2. Calibrators, reagents, materials and sera 
 
Calibrators 
Recombinant human insulin expressed in yeast (Sigma-Aldrich) was used as standard 
material. It was delivered in vials containing 50 mg of freeze-dried material and had a 
purity and potency of respectively >98% and 27.5 kIU/g (according to the manufacturer’s 
information). 4-[D10]Leu-insulin, labeled in positions 6, 11, 15, and 17 of the beta-chain 
(see Figure II.1), used as IS, was bought from Peptide Institute (Osaka, Japan). The 
producer stated a purity of 98.5%, determined by HPLC analysis.  
For the preparation of the calibration solutions, two different procedures were 
applied during the method comparison study (Procedure 1) and method validation 
(Procedure 2).  
Procedure 1: the standard stock solution was prepared by weighing and 
dissolving a minimum of 5 mg of standard material in 1 mL of a 60/40 (v/v) mixture of 50 
mM hydrochloric acid in water and glycerol. The stock solution was diluted in two 
consecutive steps with the same solvent to obtain a final concentration of 25 mg/L (0.62 
kIU/L). Immediately after preparation, the latter solution was divided into 350-µL portions 
and stored at -20 °C until the day of analysis. These portions were never used more than 
four times. Each day of analysis fresh working solutions with a concentration of 20 µg/L (= 
0.5 IU/L) were prepared. This was done by diluting a portion of the stock solution of 25 
mg/L with a 60/40 (v/v) mixture of water/glycerol containing 0.1 g/L of protease-free BSA. 
Note that two individually weighed stock solutions were always diluted to prepare a total of 
four different working solutions (2 from each stock). The stock and working solutions of 
the IS were prepared in an identical way. Thirty µL of a 60/40 (v/v) mixture water/glycerol 
containing 0.1 g/L of BSA and 10 mg/L of glargine (Lantus® from Sanofi-Aventis) were 
pipetted into the empty vial, which was vortexed before adding the standard working 
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solutions. Glargine was used in this and other steps (see also Procedure 2) because it 
proved to have a carrier effect. 
Procedure 2: the standard stock solution was prepared exactly as described in 
Procedure 1. Subsequently, it was diluted in two consecutive steps with insulin-depleted 
serum (Scipac) to obtain a final concentration of 25 mg/L (= 0.62 kIU/L). The pH of the 
insulin-depleted serum was adjusted to 7.4 by adding 100 µL of HEPES buffer (185 g/L 
HEPES acid and 8.8 g/L NaOH, both from Sigma) per mL of serum. Immediately after 
preparation, the latter solution was divided into 50-µL portions and frozen at -20 °C until 
the day of analysis. On that occasion, a frozen vial of the stock solution of 25 mg/L was 
thawed and diluted with a 60/40 (v/v) mixture of water/glycerol containing 0.1 g/L of BSA 
and 10 mg/L glargine to obtain working solutions of 20 µg/L (= 0.5 IU/L). This dilution was 
never reused. Note that two individually weighed stock solutions were always diluted to 
prepare a total of four different working solutions (2 from each stock). The stock and 
working solutions of the IS were prepared as described in Procedure 1. One hundred µL 
of a 60/40 (v/v) mixture of water/glycerol containing 0.1 g/L of BSA and 10 mg/L of 
glargine were pipetted into the empty vial and vortexed before adding the standard 
working solutions.  
In both procedures low protein-binding Sorensen® vials (BioScience Inc, West Salt 
Lake City, Ut, USA) were used. Also all volumetric steps involved in the 
preparation/sampling of the calibration solutions were gravimetrically controlled, using a 
Mettler Toledo analytical balance, type AT261 Delta Range that allowed mass 
measurements till 10-5 g. Finally, the calibrators were prepared by mixing of equivalent 
amounts  of  the  insulin  and IS working solutions. The calibration mixtures were stored at  
-20°C until the time of analysis. The analysis of calibrators taken through the sample 
preparation procedure analysis verified that they could be directly injected in the 
LC/tandem MS system. A one-point calibration procedure was used (30). 
  
Reagents and materials  
Glycerol (Sigma-Aldrich), HPLC-water (Biosolve, Valkenswaard, Holland), ACN (Romil, 
Cambridge, UK), TFA (Fluka, Buchs, Switzerland) and cyclohexane (Merck, NJ, USA) 
with pro-analyse, gradient grade, LC/MS grade and for protein use qualities, respectively. 
For IAC, Trizma® hydrochloride, Trizma® base, NaN3 and ammonium acetate were 
purchased from Sigma-Aldrich. Experiments were started with an IAC-gel made in 
collaboration with the Department of Clinical Medicine, Division of Clinical Chemistry, 
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Biomedicum Helsinki, University of Helsinki (Finland). A mouse monoclonal antibody 
(Biodesign International, Saco, ME, USA) coupled to cyanobromide sepharose (GE 
Healthcare, Diegem, Belgium) was used. The procedure used to make de IAC columns 
was taken from ‘Affinity Chromatography. Principles and Methods’ (31) and will not be 
describe in more detail. Afterwards, further optimization and final application of the IAC 
procedure was done with a commercial immunoaffinity gel from “Laboratoire 
d’Hormonologie” (C.E.R. Groupe, Marloie, Belgium). Empty Poly-Prep columns from Bio-
Rad (Hercules, CA, USA) were filled with 0.25 mL of IAC-gel. The properties of these two 
different IAC-gels are summarized in Table III.2. The gel was stored in a buffer at pH 7.4 
containing 50 mM Tris and 0.05% of sodium azide
 
in water. Sep-Pak® C18 cartridges (1 
cc, 50 mg) from Waters (Milford, MA, USA) were used for SPE after IAC.  
 
Table III.2. Properties of the IAC used columns. 
 
Self made Commercially available 
Mouse monoclonal antibody (IgG1,k) Mouse monoclonal antibody (IgG1,k) 
Affinity constant: 6 x108 M-1 - 
CNBr sepharose matrix CNBr sepharose matrix 
2 mg IgG/mL capacity 10 mg IgG/mL capacity 
0.5 mL gel/column 0.25 mL gel/column 
 
 
Sera 
The sera employed during the method development and optimization experiments came 
from the blood transfusion center of the Flanders Red Cross at Leuven. They were 
handled according to the local Ethical Committee guidelines. 
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III.2.3. Instrumentation 
 
For LC/tandem MS two different instruments were used. Experiments were started with a 
Micromass VG Quattro IITM triple stage MS (Altrincham, UK) equipped with a megaflow 
electrospray probe. It was coupled to a Kontron HPLC system Model 325 from (Milan, 
Italy) equipped with an autosampler 465 from the same brand. Nitrogen was used as the 
drying and nebulizing gas at a flow rate of respectively 450 and 14 L/h. Later on, a newer 
instrument with better performance characteristics was used. This was an Applied 
Biosystems API 4000TM triple stage MS from (Foster City, CA, USA) equipped with an 
electrospray probe and coupled to an Agilent 1100 Series HPLC and autosampler (Palo 
Alto, CA, USA). In Table III.3, the settings of the two instruments are summarized. 
 
Table III.3. Main settings of the MS configurations used for the measurement of human insulin (transition 
monitored m/z 1453 to 226). 
 
Setting VG Quattro IITM API 4000TM 
Cone voltage / Declustering potential 60 V 50 V 
Capillary / Ion spray voltage 4 kV 5 kV 
Drying / nebulising gas 450 / 14 L/h (nitrogen) - 
Curtain gas / Gas 1 and 2 - 35 (nitrogen) / 65 
EP / CXP - 11 / 12 
Source temperature 175 °C 500 °C 
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III.2.4. Optimization experiments 
 
III.2.4.1. Stability of standard solutions 
 
The stabilization effects of glycerol, albumin, glargine and insulin-depleted serum were 
investigated. 
 
III.2.4.2. Optimization of HPLC conditions 
 
Experiments were done with a Hamilton PRP-3 column (50x2.1, 3 µm particle size) (Reno, 
NV, USA), with a Waters XTerra column (2.1x10 mm, 5 µm) and with Waters XBridge 
columns (Milford, MA, USA). From the latter, different lengths (10 mm and 150 mm) and 
particle sizes (3.5µm and 5µm) were tested. 
 
III.2.4.3. CID experiments with different instruments and collision gases 
 
CID experiments were performed for the 4-times protonated molecular ion (m/z 1453) with 
the Micromass VG Quattro IITM and the API 4000TM MS configurations. The collision gases 
tested were helium, argon, and nitrogen in the VG Quattro IITM. The API 4000TM was only 
operated with nitrogen, the standard installed gas for CID. Parameters that were 
optimized comprised the gas pressure and the CID energy. All the other MS settings are 
summarized in paragraph III.2.3 (see Table III.3). 
Samples were introduced by an online HPLC system, under the same conditions 
as described in paragraph III.2.6. Chromatography was performed with a XBridge C18 
column (10x2.1 mm, 5 µm particle size) connected to a prefilter from Alltech (Deerfield, II, 
USA). 
All the measurements were done in the positive wrong way round electrospray 
ionization (wESI+) mode and monitoring the CID spectra of the four times protonated 
molecular ion [M+4H]4+ (m/z 1453) of human insulin. CID-scans in the range from m/z 50 
to 400 were acquired at one scan per second in both instruments. 
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III.2.5. Sample preparation procedure development 
 
During the development of the sample preparation procedure two different methods were 
created, one consisted in a combined IAC-SPE (see Figure III.1.A) and the other in a two-
step SPE procedure (see Figure III.1.B). The first was already presented and described in 
detail in the doctoral thesis of Dr. K. Van Uytfanghe. Below the two-step SPE procedure is 
described in detail together with the way both procedures were evaluated and compared. 
For a detailed description of the combined IAC-SPE method see paragraph III.2.7. 
 
 
Mix reverse phase-
anion exchange SPE
drying, reconstitution
Reverse phase SPEIAC
HPLC-MS analysis
2-step SPEIAC + SPE
Serum
Reverse phase SPE
+ 0.1% TFA+ Binding buffer
 
 
Figure III.1. Schematic representation of both developed methods. 
 
Two-step SPE procedure 
This procedure is schematically presented in Figure III.1.B. Samples were diluted 1:2 with 
0.1% TFA prior to SPE with Sep-Pak® C18 3 cc (200 mg). Sep-Pak® C18 cartridges were 
preconditioned by consecutive wetting with 2 mL of ACN and 2 mL of 0.1% TFA. After 
loading the diluted serum samples twice, cartridges were washed consecutively with 2 mL 
20/80/0.3 (v/v/v) ACN/water/TFA, 2 mL 30/70 v/v ACN with 0.1% TFA/dichloromethane 
A B 
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and 0.7 mL 20/80/0.1 ACN/water/TFA. Elution was performed with 2 mL 35/65/0.6 
ACN/water/TFA in a test tube containing 0.1 mL HPLC-water and 300 ng glargine. Oasis® 
MAX 1 cc (30 mg) cartridges were preconditioned by consecutive wetting with 1 mL ACN 
and 1 mL of HPLC-water. Prior to loading of the extracts  onto  the  Oasis®  MAX  
cartridges,  7  µL  of  25%  ammonia  were  added to the  
Sep-Pak® eluate. The cartridges were washed consecutively with 1.5 mL 
23.33/76.67/0.4/0.42 ACN/water/TFA/NH4OH (i.e., 2 mL of the eluent for elution from Sep-
Pak® with 1 mL of water and 50 µL of 25% ammonia) and 1 mL of 5/95/0.5 
ACN/water/acetic acid. Elution was done with 1.2 mL 80/20/0.5 ACN/water/acetic acid in a 
vial containing 100 µL of ACN. Finally, the extracts were evaporated to dryness at 50 °C 
under nitrogen
 
(~30 min) and stored at -20 °C until analysis. Before LC/tandem MS 
analysis, 0.25 mL of cyclohexane were added, vortexed and removed. The remaining 
residue was dried and reconstituted in 50 µL of a 10/90 (v/v) mixture of ACN/water for 
injection into the chromatographic system (5 to 45 µL, depending on the concentration). 
The two-step SPE procedure was qualitatively compared with the combined 
IAC/SPE procedure. An optimized version of the combined IAC/SPE procedure is 
described in detail in the final method presented in paragraph III.2.7, but for this 
experiment (performed in an early stage of the method development), the procedure was 
slightly different. The IAC columns contained 0.5 mL of the self made gel (paragraph 
III.2.2). The last washing step of the IAC was done with 0.5 mL of 0.05% TFA. Elution was 
performed by twice adding 0.4 mL of 0.05% TFA.  
The two techniques were evaluated by comparing representative ion 
chromatograms of an extracted serum pool with a concentration of 5 µg/L (124 mIU/L), 
from which 2 mL were taken through analysis. 
 
Optimization of the C18 SPE procedure used in the IAC method 
Reverse phase cartridges (C8 or C18) from different brands and with different packing 
size were tested, more specifically: Waters Sep-Pak C18 1 cc (50 mg) (Milford, MA, 
USA), Oasis HLB 1 cc (30 mg) also from Waters, Varian SPEC C8 and C18 1 cc (15 
mg) (Palo Alto, CA, USA) and 3M Empore C18 1 cc (4mg) with high (12 µm particle size) 
and standard (55 µm particle size) densities (St. Paul, MN, USA). Additionally, the 
different cartridges were tested in the normal flow direction and in the “reverse-loading 
mode” (see Figure III.2). The upside down mounting was done by connecting (with tubing) 
the loading side of a cartridge containing the solid phase to the vacuum manifold. 
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Subsequently, the cartridge's elution side was connected to the same side of an empty 
cartridge, serving as the solvent container. 
The cartridges were compared by loading 50 µL of a mixture 40/60 (v/v) 
glycerol/water with 0.4 g/L BSA containing 1 ng of insulin. Cartridges were then washed 
with 1 mL of 10/90/0.1 (v/v/v) ACN/water/TFA and eluted with 100 – 150 µL of 70/30/0.1 
(v/v/v) ACN/water/TFA for the 4 and 15 mg packing cartridges respectively (following 
manufacturer instructions), while with 250 µL for the cartridges with 30 and 50 mg. 
 
vacum manifold
two-way stopcock
connecting tubing
Sep Pak C18 1 cc
empty cartridge
connecting tubing
 
 
Figure III.2. Schematic representation of the technique used for loading the cartridge in the opposite direction 
of normal flow. 
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III.2.6. Establishment of the relationship between the WHO and the Sigma insulin 
standard 
 
For the comparison of the WHO 1st IRP (66/304) and the Sigma recombinant insulin 
standard material the following procedure was applied. Two ampoules of the WHO 
standard were diluted in 60/40 (v/v) glycerol/50 mM HCl in water until a concentration of 
130 µg/g. At the same time, two stock solutions of around five µg/mg of the Sigma 
standard were prepared by weighing five mg of insulin and dissolving them in 1 mL of 
40/60 (v/v) glycerol/50 mM HCl in water. The Sigma stock solutions were diluted a second 
time with 40/60 (v/v) glycerol/50 mM HCl in water also until a concentration of 130 µg/g. At 
continuation, the Sigma and WHO intermediate solutions were diluted with insulin-
depleted serum to a final concentration of 0.2 µg/g. This dilution took place in two steps, 
first some insulin-depleted serum was pipetted in the empty vial, then supplemented with 
the appropriate amount of standard solution and finally insulin-depleted serum was added 
until the desired total volume. Note that the pH of the insulin-depleted serum was adapted 
to 7.4 with HEPES buffer by adding 100 µL of this buffer (185 g/L HEPES (acid); 8.8 g/L 
NaOH) per each mL of serum. The IS was diluted in 60/40 (v/v) glycerol/water with 0.1 g/L 
BSA also to a final solution of approximately 0.2 mg/L. From each of the final solutions 
three calibration mixtures were prepared, i.e., standard/IS mixtures. First, 200 µL of the 
standard solution were pipetted, followed by the appropriate volume of IS solution in order 
to approximately achieve the isotope ratio of one. Afterwards, the sample preparation as 
described below in paragraph III.2.7 was performed on these mixtures. Analysis of these 
mixtures was carried out by alternating analysis of Sigma and WHO standards. The 
results of isotope ratios standard/IS were calculated and normalized with the mass ratios 
from standard/IS. The mean ratios of isotope ratio/mass ratio from the Sigma and WHO 
calibrators were compared. The difference between the ratios of each series was 
assessed for significance with a two-sided Student t-test (95% probability level).  
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III.2.7. Analytical procedure for serum insulin 
 
The sample preparation procedure for the determination of insulin in serum consisted in a 
combined IAC – SPE procedure. A schematic representation of this procedure can be 
seen in Figure III.1.A. This procedure was validated and applied during the method 
comparison with the routine insulin immunoassays. The procedure was already described 
in detail in the doctoral thesis of Dr. K. Van Uytfanghe but will be mentioned here again for 
completeness of information. 
 
Sampling and calibration procedure 
The procedure started with gravimetric sampling of the serum, between 0.3 mL (minimum) 
and 4 mL (maximum) depending on the concentration (based on data available from the 
Roche immunoassay) and available volume. Ideally, an absolute amount of insulin of 2 ng 
was processed. A known amount of IS was added to obtain an isotope ratio of 1:1 within 
±15%, and the samples were equilibrated for at least 30 min. Samples with a total amount 
of insulin lower than 0.6 ng were analyzed at an isotope ratio of 0.5:1, together with a set 
of calibration mixtures prepared at the same ratio.  
The calibration procedure was based in the principle of one point calibration (30). 
The measurement procedure consisted of the analysis of three calibrators followed by the 
analysis of four samples, three calibrators and so on. This alternation of calibrators and 
samples was done to compensate any eventual drift in the response of the instrument. 
 
Immunoaffinity chromatography sample preparation procedure  
IAC was performed with 0.25 mL of the commercially available gel (see paragraph III.2.2). 
The gel was stored in a buffer at pH 7.4 containing 50mM Tris/0.05% sodium azide in 
water. The immunoaffinity gel containing columns were used in the gravity feed mode. 
Conditioning was done by adding 3 mL of binding buffer (50 mM Tris, pH 7.8 in water) for 
immediate application of up to 4 mL of serum (depending on the concentration) diluted 1:1 
with binding buffer. Then, the gel was rinsed with 5 mL of binding buffer, 4 mL of 10 mM 
ammonium acetate (pH 4.5) and 0.2 mL of 0.1% TFA in water (this first rinse with TFA did 
not cause elution since the volume corresponds with the dead volume of the column). 
Human insulin and 4-[D10]Leu-human insulin were subsequently eluted with two times 0.4 
mL 0.1 % TFA in water, taking care that a time interval of 5 min elapsed between 
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application and elution of the TFA solutions. Finally, the IAC columns were re-equilibrated 
with 5 mL of binding buffer.  
The eluate from IAC was loaded into a Sep-Pak® C18 cartridge, mounted upside 
down in order to perform a reverse loading mode (see Figure III.2). The cartridge was 
conditioned with 2 mL of ACN and 2 mL of 0.1% TFA in water. After being loaded, the 
cartridge was washed with 2 mL of 10/90/0.1 (v/v/v) ACN/water/TFA. Finally, it was 
mounted in the normal flow direction for   The extracts were evaporated to dryness at 50 
°C with nitrogen and the residues stored at -20 °C until analysis. Before processing by 
LC/tandem MS, 0.25 mL of cyclohexane were added, vortexed and removed. The 
remaining residue was dried and reconstituted in 50 µL of a 10/90 (v/v) mixture of 
ACN/water for injection into the chromatographic system of 15 to 45 µL (depending on the 
concentration). 
 
LC/tandem MS measurement procedure 
MS was done with an API 4000TM system, operated in wESI+ mode and connected with 
an HP 1100 HPLC system. The latter was equipped with a XBridge C18 column (2.1x10 
mm, 5 µm) maintained at room temperature. Gradient elution was done with eluents A and 
B containing ACN and water (in a v/v ratio of 10/90 and 70/30, respectively) and 0.0025% 
ammonium hydroxide. The percentage of ACN was increased from 10% to 40% in 3 min 
at a flow rate of 0.25 mL/min and kept constant during 3 min. Afterwards, it was increased 
to 70% in the next 0.1 min and kept constant again for 3 min to clean the column. Finally, 
the column was re-equilibrated with eluent A for 5 min. For a schematic representation of 
the HPLC gradient see Figure III.3 below. 
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Figure III.3. Schematic representation of the HPLC-gradient. 
 
SRM transitions of the four times-protonated molecular ions [M+4H]4+  from m/z 
1453 to 226 (insulin) and 1463 to 226 (4-[D10]Leu-insulin) with dwell time of 0.5 s were 
monitored. This resulted in at least 15 scan cycles under the peak. The declustering 
potential was 50 V, the collision energy was 85 eV and the N2 collision gas setting was 12. 
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III.2.8. Method validation 
 
The IAC-LC/tandem MS measurement procedure was validated. The following 
experiments and materials were employed.  
 
Specificity 
Specificity was assessed indirectly by visual inspection of chromatograms obtained in the 
method comparison study. Indirect evidence was also gained from the accuracy and 
precision studies. The presence of any interference would affect the precision and 
accuracy to a different extent at different concentrations. In order to study the 
interferences at the transition typical for the 4-[D10]-Leu-insulin, analysis of several serum 
samples selected from the method comparison study without the addition of IS were 
measured. 
 
Limit of detection and quantification 
The determination of the LOD was done by injection of calibration solutions. The LOD was 
calculated as the quantity of insulin on column necessary to obtain a S/N of 3. 
 The LOQ was estimated from the analysis of a pool of insulin-depleted serum 
supplemented with insulin to a final concentration of 0.0796 µg/L. 
 
Recovery of sample preparation procedure 
A preliminary estimation of the absolute recovery of the insulin extracted from the serum 
was determined with a serum pool that was divided in eight portions of 2 mL. Two portions 
were supplemented with 344 fmol (2 ng) of IS. The other six portions were purified and 
344 fmol of IS were added at three different stages (n=2) of the sample preparation 
procedure, more exactly, after IAC, after SPE and after drying of the SPE-eluates. The 
recovery (in %) was calculated from the comparison of the isotopic ratios of the different 
portions.  
 
Ion suppression 
The suppression in the ionization process was qualitatively studied through the 
comparison of the absolute signal of IS in a calibration solution and in a purified sample 
were the IS was added after the drying step (n=2). 
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Precision, accuracy and trueness 
The performance of the ID-LC/tandem MS procedure (imprecision, accuracy and 
trueness) was validated with insulin-depleted serum supplemented with human insulin to 
obtain three pools, a low pool at 0.0796 µg/L (= 1.97 mIU/L) (LOQ), a medium and high 
level pool at 0.769 µg/L (= 19.0 mIU/L) and 5.56 µg/L (= 137.8 mIU/L), respectively. 
Aliquots were stored at -20 °C and analyzed in duplicate on 6 different days (n = 12). The 
insulin content (±95% CI) of the insulin-depleted serum was determined beforehand.  
For the recovery data, two-sided 95% CI were calculated and a 1-sample t-test 
was performed. Statistical data analysis was done with CBstat, Version 5.1 (CBstat 
software) and MedCalc, Version 9.2.0.0 (MedCalc software). Model II ANOVA was used 
to calculate the CVwithin, CVbetween and CVtotal (%). The CVtotal was obtained from the 
combined CVbetween and CVwithin (square root of the sum of the squared CVbetween and 
CVwithin).  
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III.2.9. Method comparison study  
 
The study was purposely undertaken in an early developmental stage of the ID-MS 
procedure in order to have a fast answer on questions about the feasibility of the project, 
to know the expected impact on immunoassay results after recalibration and to be able to 
do a focused refinement of our ID-MS procedure. That is the reason why the protocol for 
preparation of calibrators is slightly different between the method comparison studies and 
the method validation. 
 
Measurement strategy 
For the method comparison, 80 serum samples from 16 ambulatory patients (four males 
and 12 females, aged between 21 and 74 years) from Ghent University Hospital were 
used. The patients had been subjected to an oral glucose (75 g) tolerance test after 
overnight fasting. The insulin tests were ordered by the endocrinologist for assessment of 
glucose tolerance, glucose handling, beta cell function and degree of insulin sensitivity in 
subjects with morbid obesity and/or other risk factors for insulin resistance and glucose 
intolerance. Handling of patient samples was done according to the local Ethical 
Committee guidelines. Blood was drawn into Venosafe VF-106SAS tubes (Terumo) 
before the glucose load and also after 30, 60, 120 and 180 min. The collected blood was 
allowed to clot for at least 30 min and centrifuged at 1500 g for 10 min. The fasting blood 
samples were transported to the laboratory within 30 min of withdrawal, whereas the 
remaining samples were received within 30 min of the last collection. Then, the analysis 
was immediately started with the four immunoassays. The remaining serum was 
transported ice-cooled to the MS laboratory. There, the samples were immediately 
processed by combined IAC/SPE as described above. The evaporated extracts were 
stored at -20 °C until LC/tandem MS analysis the next day.  
Each sample was measured singly with each of the routine immunoassays. The 
measurements in the ID-LC/tandem MS laboratory were done once according to a 
measurement protocol with bracketing of the patient and control samples (maximum six) 
between two times three calibrators, which allowed analysis of samples of two stimulated 
patients per working day. The values of all calibrators were used for the calculation of the 
sample concentration. Measurement of the 16 stimulation curves by both the ID-
LC/tandem MS and routine laboratory was done in eight different analytical runs (batches 
of 10 samples and one control sample) spread over three weeks. The quality of each 
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analytical run was controlled by the use of a high level lyophilized control material 
(estimated mean = 4.426 µg/L; CVtotal = 2.6%; n=8) from INSTAND e.v. (Düsseldorf, 
Germany). 
 
Routine measurement procedures 
The method comparison was done with the four following assays: 
electrochemiluminescence immunoassay for use on the Diagnostic Products Corporation 
(DPC) Immulite® 2000 Insulin from (Los Angeles, CA, USA), the Roche Diagnostics 
GmbH Modular Analytics E170 (Basel, Switzerland) immunoassay analyzer, the Abbott 
AxSYM insulin microparticle enzyme immunoassay (Abbott Park, Illinois, USA) and the 
Beckman Coulter Access Ultrasensitive insulin chemiluminescent immunoassay 
(Fullerton, CA, Los Angeles). All assays are calibrated against the WHO insulin 1st IRP 
66/304 (NIBSC). All measurements with the commercial insulin immunoassays were 
performed with the same batch and in accordance with the respective manufacturer's 
instructions for use. Each assay's performance was controlled either with assay specific 
control samples (for DPC the insulin Controls LINC1 and LINC2 with assigned target 
values of 9.2 and 48 mIU/L; for Abbott the AxSYM insulin L, M and H with targets of 8, 40 
and 120 mIU/L), with commercial control materials (for Beckman the Lyphochek 
Immunoassay Plus Control Level 1, 2 and 3 from Bio-Rad with assigned values of 7.1, 36 
and 95 mIU/L) or with in-house prepared serum pools (for Roche) targeted before at 11.1 
and 60.0 mIU/L. 
 
Statistical methods and graphical presentation 
The results from the method comparison were investigated by scatter-plots and 
correlation and Deming regression analysis (CBstat software version 5.1 from K. Linnet, 
Risskov, Denmark). The two highest concentration values were not taken into account for 
the regression and correlation analysis because they are outliers with respect to the 
distribution of the insulin concentrations. In the graphs, however, the regression line is 
extrapolated to show the performance of the assays in the high concentration range. 
Further, the results were investigated by difference plots containing total error limits 
derived from the combined imprecision of both measurement procedures (CVmp) 
(calculated with Formulas III.1 and III.2) and total error limits specified by the ADA (32%). 
The latter limits are derived from the biological variation of serum insulin (3). 
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CVCV
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mp +=  
 
Formula III.1. CV of the method pair. Note that n is the number of repeated measurements of the same 
sample with each method. 
 
 
mpCV x 1.96 TE =  
 
Formula III.2. Total error due to the combined imprecision of both methods. 
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III.3. RESULTS AND DISCUSSION  
 
III.3.1. Method development and optimization 
 
Note, that since the method development was published (32), the method has been 
refined and further applied to the measurement of 45 serum samples to be used in an 
international project for the evaluation and standardization of insulin immunoassays. This 
work has been performed under an ADA grant (29). Unfortunately, at this point, the ADA 
did not consent to the use of the data in the current thesis. Therefore, only some general 
statements can be made about the progress of the method since. 
 
III.3.1.1. Stability of standard solutions 
 
Many factors can cause the degradation or loss of proteins in a solution (33), like 
oxidation, contamination of proteases from our skin, polymerization, loss due to 
adsorption and damage during the freezing process. In the case of insulin, the 
desamidation at acidic pH (Asn in position A21) and at neutral pH (Asn in position B3) 
may also take place. Indeed, in the preparation of standards without any additives, 
differences of up to 20% were observed in isotope ratios between calibrators prepared 
from different working solutions. This was attributed to decomposition or loss due to 
absorption.  
 Many techniques have been described to stabilize proteins and to avoid their 
adsorption: addition of trehalose to decrease polymerization; maintaining the pH at a 
higher value than the pKa (34) of the protein to prevent desamidation at Asn residues; use 
of EDTA to complex any metals which can produce aggregation or oxidation of –SH 
groups; storing solutions at -20 °C without freezing by adding 30 to 50% glycerol (or 10 to 
50% isopropanol) (35); adding albumin; rapid freezing with liquid nitrogen; use of 
antioxidants; use of gloves or protease inhibitors; avoiding aeration or foaming by mixing 
gently; use of LBP or coated vials and tips. 
 We stabilized insulin by making solutions in 40/60 (v/v) glycerol/water with 0.1 g/L 
BSA (32). This allowed the direct injection of the standards in the HPLC system. 
Unfortunately, longer-term experience demonstrated that this was not sufficient to 
guarantee stability within the 5% limit for systematic error set by the ADA. Therefore, we 
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had to make stock and standard solutions in insulin-depleted serum. This required taking 
the standards through the complete analysis. 
 
III.3.1.2. Optimization of the HPLC conditions 
 
All current LC/MS measurement procedures for quantitative analysis of human insulin in 
serum work under acidic LC conditions and ESI+. The HPLC-MS procedures mainly 
utilized TFA (25-27), while one of the off-line procedures made use of acetic acid (24). 
Triggered by the development of base-stable C18 reversed phase columns, we 
investigated LC under alkaline conditions (with ammonia) and operating the mass 
spectrometer in the wESI+ mode. First chromatograms of insulin standards were 
encouraging: insulin eluted as a single peak with good symmetry and sensitivity (see 
Figure below corresponding to an XBridge column). 
 
 
 
 
Figure III.4. Chromatogram corresponding to a sample of 0.75 µg/L (19 mIU/L). 
 
Therefore, we further evaluated a PRP-3 column (50x2.1, 3 µm particle size), an XTerra 
C18 column (2.1x10 mm, 5 µm), and various XBridge C18 columns (2.1x10 mm, 5 µm; 
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2.1x10 mm, 3.5 µm; 2.1x150 mm, 5 µm). The best results were obtained with the short 
XBridge columns (see below for chromatograms of processed samples). The advantage 
of the short columns is their price, which allows treating them as “disposables”. While the 
method comparison study has been done with the 5 µm columns, experiments are being 
performed to investigate the long-term robustness of the 3.5 µm column. The latter is 
somewhat superior in terms of resolution and S/N ratio. 
Unfortunately, it was not possible to directly compare the sensitivity of our 
procedure with those of the previously published procedures, because they applied 
different instruments, different scan conditions (e.g. short scan over the five-times 
protonated molecular ion (24), bigger scan and measuring the three times protonated 
molecular ion (26), product ion scan (27), or SRM (25)) or off-line HPLC (24, 26). 
However, with our MS configuration and conditions, the new procedure was ~25 times 
more sensitive than a procedure optimized with 0.04% TFA. 
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III.3.1.3. Optimization of MS conditions: CID experiments 
Parent spectrum 
The parent spectrum of insulin in the wESI+ mode (Figure III.5) is dominated by the three-
, four- and five-times protonated molecular ions (m/z 1937, 1453 and 1162.6, 
respectively). The four-times protonated molecular ion, being the most abundant ion of 
insulin in the wESI+ mode, was selected for CID. 
 
 
 
Figure III.5. Mass spectrum of human insulin obtained in positive mode on the VG Quattro IITM. m/z 1162.6 
corresponds to [M+5H]5+, 1453 to [M+4H]4+ and 1937 to [M+3H]3+. 
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CID spectra of m/z 1453 
Figures III.6.A and III.6.B show the product ion mass spectra of m/z 1453 under CID 
conditions optimized for the ions at m/z 110 and m/z 226, respectively. 
The optimized spectrum for m/z 110 (Figure III.6.A) is dominated by fragments of 
insulin amino acids like valine (m/z 72), leucine or isoleucine (m/z 86), histidine (m/z 110), 
phenylalanine (m/z 120), arginine (m/z 129) and tyrosine (m/z 136). Some product ions 
can correspond to amino acid side chain fragments (m/z 69, 72 and 83) (38) (for reviews 
about the low mass (m/z < 200) region of the CID spectra of proteins see: 36-38).  
The spectrum optimized for m/z 226 (Figure III.6.B) is dominated by the m/z 226 
fragment, which corresponds to the y3-y1 fragment of the insulin β-chain (lysine-proline). 
The fragment at m/z 345 corresponds to the complete y3 fragment (threonine-lysine-
proline) (39). 
 
 
 
 
Figure III.6. CID-spectra of m/z 1453 obtained with the Quattro II, optimized for m/z 110 (A) and m/z 226 (B). 
 
 
A 
B 
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Comparison of various collision gases in the VG Quattro IITM configuration 
Table III.4 shows the optimal conditions for the generation of m/z 226 and m/z 110 CID 
fragment ions of m/z 1453 precursor ion from insulin using different collision gases. In 
general, it can be seen that the collision energies for the formation of the fragment ion m/z 
110 were higher than for the formation of the m/z 226 fragment ion.  
For argon, the collision energy and the gas pressure was lower for both transitions 
than for nitrogen. Helium requires even higher gas pressures and collision energies. 
Therefore, it was impossible to optimize the conditions for the formation of the fragment 
m/z 110. On the other hand the spectra were quite similar to the various gases under 
optimized conditions. 
For our application, argon and nitrogen gave the same sensitivity. However, the 
advantage of nitrogen is its lower cost.   
 
Table III.4. Optimal MS conditions for the generation of the most sensitive CID fragment ions of m/z 1453 
precursor ion in the Micromass VG Quattro IITM MS using different CID gases. 
 
 Argon Nitrogen Helium 
m/z eV mBar eV mBar eV mBar 
226 25 3.3E-3 75 1.1E-2 130 4.0E-2 
110 145 3.3E-3 190 1.1E-2 
Could not be 
optimized 
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Comparison between the VG Quattro IITM and API 4000TM configurations 
Figure III.7 shows the CID-spectra of m/z 1453 obtained with the API 4000TM, optimized 
for m/z 110 (A) and m/z 226 (B). 
 
 
 
Figure III.7. CID-spectra of m/z 1453 obtained with the API 4000TM, optimized for m/z 110 (A) and m/z 226 (B). 
 
First, it should be noted that it was not possible to find conditions in the API 4000TM 
to obtain m/z 110 as the most intense ion in the spectrum (see Figure III.7 A). This is 
mainly attributed to the pressure limitation of the API 4000TM collision cell. Unfortunately, 
we were unable to install argon as collision gas on the API 4000TM. According to contacts 
with the company we had to “do this at our own risk”. A further limitation is the maximum 
usable collision energy of about 190 eV (this voltage depends also on other voltages used 
in the CID mode).  
On the other hand, the spectra optimized for m/z 226 were quite similar with the 
VG Quattro IITM and the API 4000TM (compare Figures III.6 B and III.7 B). 
B 
A 
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Selection of the most selective and sensitive SRM transition 
On the VG Quattro IITM, m/z 110 was the most sensitive transition, five times more 
than m/z 226. On the API 4000TM, the transition to m/z 129 was the most sensitive one. 
However, the transition to m/z 226 was the most selective one on both instruments. The 
API 4000TM was approximately 10 times more sensitive for that transition than the VG 
Quattro IITM. 
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III.3.1.4. Development of sample preparation  
 
Figure III.8 shows the chromatograms obtained with the two-step SPE procedure (A) and 
the IAC procedure (B) for a sample containing 5 µg/L (860 pmol/L) of insulin. Note that the 
less selective transition to m/z 110 was monitored in order to better visualize the 
differences in the sample preparation procedures. The visual inspection of the 
chromatograms shows that the IAC procedure gives clearer chromatograms. Also, 
pressure increases were observed when injecting samples purified by the two-step SPE 
procedure. Therefore, the IAC procedure was finally chosen for sample preparation. 
 
 
 
 
Figure III.8. Chromatograms obtained after purification of a sample with 5 µg/L (860 pmol/L) of insulin with 
two-step SPE (A) and IAC (B). 
 
Note, however, that the IAC columns are relatively expensive. This requires using 
the columns several times. The experience gained up to now did not give an unequivocal 
A 
B 
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indication of how many times the columns could be used. Depending on the samples 
purified and the columns prepared, the columns could be used 6 to 20 times. Future 
investigation is needed to increase the robustness of the IAC purification step. 
 
Optimization of the C18 SPE procedure used in the IAC method 
Cartridges with lower packing size were tested in order to reduce elution volumes 
and hence increase recoveries in the preconcentration step. Reducing elution volumes to 
approximately 100 µL was possible, unfortunately, worse recovery results were obtained 
than by using Sep-Pak C18 1cc (50 mg) in the “reverse-loading mode” (see Figure III.2). 
The idea behind the reverse loading of the SPE cartridges was restricting the adsorption 
of insulin to a small part of the solid phase, hence, to minimize losses and reduce the 
elution volume. 
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III.3.1.5. Relationship between the WHO and the Sigma insulin standard 
  
All development, validation and application experiments described in this dissertation 
were done with commercially available recombinant human insulin from Sigma with a 
purity >98%. The quality of this material was good enough for the purpose of the research 
but to be able to evaluate the calibration status of the routine immunoassays, the link 
between this standard and the first IRP for insulin (66/304) must be determined. Note that 
all commercial immunoassays are calibrated with this WHO material (1). This international 
standard is prepared from human pancreas extracts and is distributed in ampoules of 1 
mL that contain approximately 130 µg of insulin and 4 mg of sucrose. Per definition, one 
ampoule contains three IU of insulin, with a filling variation of 1.08%. A great disadvantage 
of this international standard is that it is not defined in terms of mass. That has the 
consequence that the link between the international unit (IU) and the effective content of 
insulin in this standard (expressed in g or mol) is not yet established. In addition, several 
conversion factors are use, varying from 6 to 7.5 (conversion from IU to pmol/L) (1). This 
is also the reason why this standard was not used for our candidate RMP as primary 
calibrator. It is also important to mention that in the international standardization of insulin 
immunoassays organized by ADA and IFCC it will be necessary the use of a state-of-the-
art primary calibrator. This can be a commercially available recombinant insulin 
preparation like the one used in our experiments but it should preferably be certified by a 
metrological institute such as NIST (National Institute of Standards and Technology) or 
IRMM (Institute for Reference Materials and Measurements). 
Table III.5 lists the results obtained for the measurements of the WHO and the 
Sigma standard. The results indicate that the insulin content of the WHO standard is 
approximately 9% lower than that of the Sigma standard (P = 0.0005 in the t-test). 
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Table III.5. Results from the comparison between the WHO and Sigma standard 
 
Stock 
Weight 
ratio (WR) 
Isotope 
ratio (IR) 
Ratio 
IR/WR 
Mean ratio 
Overall 
mean 
CI* 
Sigma 1 1.0063 1.2282 1.2205 1.2356 1.2198 2.27% 
 0.994 1.2204 1.2278    
 1.0042 1.2638 1.2585    
Sigma 2 1.0241 1.2522 1.2227 1.2040   
 1.0179 1.2346 1.2129    
 0.9999 1.1763 1.1764    
WHO 1 0.9857 1.117 1.1332 1.1196 1.1074 1.85% 
 0.9886 1.1141 1.1269    
 0.994 1.0921 1.0987    
WHO 2 0.9898 1.0766 1.0877 1.0951   
 0.9918 1.0789 1.0878    
 1.02 1.132 1.1098    
Difference Sigma versus WHO        9.2%  
 
* 95% CI for overall mean 
 
Chapter III. Insulin: Results and discussion 
 
106 
III.3.2. Method validation 
 
Specificity 
Figure III.9 shows representative chromatograms for processed serum samples with 
respectively concentrations of 0.174 µg/L (30 pmol/L), 0.918 µg/L (158 pmol/L) and 2.904 
µg/L (500 pmol/L). They show a nearly symmetric insulin peak with a base width of ~0.3 
min and a baseline that is stable and interference-free over the entire chromatographic 
run.  
Dedicated interference studies, for example with proinsulin or split-products, have 
not been performed yet. Since the mass spectrometric point of view, these substances are 
unlikely to interfere, but, as those may interfere with immunoassays they are usually 
tested also in a mass spectrometric procedure. 
 
 
 
 
 
Figure III.9. Chromatograms obtained for processed serum samples containing 2.904 (A, B), 0.918 (C, D) and 
0.174 (E, F) µg/L of human insulin (500, 158 and 30 pmol/L respectively). A, C, E: from m/z 1453 to 226; B, D, 
F: from m/z 1463 to 226. 
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Indirect evidence for the specificity of the method was also gained from the 
accuracy and precision studies. The presence of any interference would affect the 
precision and accuracy to a different extent at different concentrations. These data (see 
Table III.6) did not indicate interference problems. 
The absence of interference at the transition of the IS could be demonstrated by 
analysis of several samples from the method comparison study without the addition of IS. 
 
Limit of detection and quantification 
The LOD (defined as S/N = 3), estimated from the injection of consecutively diluted 
standard solutions, was 3.5 pg (0.6 fmol or 86 nIU). The LOQ (defined as S/N = 10) was 
0.07 µg/L (12 pmol/L or 1.83 mIU/L). This LOQ and the described application on patient 
samples (see Figure below) document that the measurement procedure is suitable for 
quantification of insulin in human sera at concentrations typical for the reference range 
0.070-0.87 µg/L (12–150 pmol/L or 1.7-21.6 mIU/L) and after glucose stimulation (up to 
11.6 µg/L (2000 pmol/L or 288 mIU/L)). 
 
 
 
 
 
Figure III.9. Chromatogram corresponding to 138 pg (3.4 µIU) of insulin on column from a sample analyzed 
during the method comparison studies. 
 
S/N = 32 
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Recovery of sample preparation procedure 
Preliminary validation of the procedure showed a total recovery of 30–40%, as estimated 
from the peak areas obtained for processed serum samples in comparison to those of the 
calibrators. From further experiments a loss of 10–15% was observed in each of the 
sample pretreatment steps, i.e., IAC, SPE, drying and sample transfer.   
The sample transfer step was investigated in somewhat more detail. Often, the 
dried extract residue after processing of the sample is redisolved and transferred to an 
insert in order to be able to inject the maximum of this solution. This transfer from the 
original vial to an insert can result in losses due to adsorption to the pipette tip, the glass 
insert as well as due to the fact that is impossible to transfer 100 % of the solution. 
Therefore, it was our objective to inject the sample directly from the evaporation vial. 
Different sort of vials from different brands and with different shapes were tested. Finally, 
the best recovery was found with glass vials having a conic bottom. For the injection of 
calibrators, PBP vials were used because they gave a somewhat better sensitivity than 
the conical glass vials. This may be attributed to adsorption to the glass or formation of 
adduct ions with ions coming from the glass. PBP vials, however, could not be used as 
samples because of considerably longer drying times. 
 
Ion suppression 
The absolute signal of IS in a calibration solution and in a purified sample were the IS was 
added after the drying step were of the same order in both instruments. This indicates the 
absence of ion suppression on both, the VG Quattro IITM and the API 4000TM instruments.  
 
Precision, accuracy and trueness 
The preliminary performance characteristics of the ID-LC/tandem MS procedure are 
presented in Table III.6. The insulin content (95% CI) of the insulin-depleted serum used 
to prepare the three pools was estimated to be 8 ng/L (1-15 ng/L) (0.02-0.37 mIU/L) (n = 
6). The within-run imprecision ranged from 3.2 to 6.3%, the total imprecision from 4.9 to 
12.1% (listing sequence from the high to the low pool). In all cases the between-run 
precision was greater than the within-run precision. Analysis of the low pool was used to 
confirm that our measurement procedure met the LOQ demand of the ADA Workgroup. 
The average S/N ratio obtained at the LOQ was 25. This LOQ was confirmed by the 
analysis of a real patient sample (lowest concentration 0.073 µg/L or 1.83 mIU/L). The 
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recovery of insulin added to insulin-depleted sera ranged from 101.8 to 104.1% (identical 
listing sequence as before). 
 
Table III.6. Precision and trueness data of the ID-LC/tandem MS procedure. 
 
Precision data (design: duplicates on 6 days (n = 12)) 
 Sample 
 Low (= LOQ) Middle High 
Mean (µg/L) 0.0829 0.792 5.656 
CVwithin (%) 6.3 3.5 3.2 
CVbetween (%) 10.3 5.0 3.8 
CVtotal (%) 12.1 6.1 4.9 
Trueness data (design: duplicates on 6 days (n = 12)) 
  
 
Sample 
  Low (= LOQ) Middle High 
Target# (µg/L) 0.0796 0.769 5.556 
Mean (µg/L) 0.0829 0.792 5.656 
95% CI (%) 11.8 5.8 4.6 
Recovery (%) 104.1 102.9 101.8 
LCL$ (%) 92.4 97.1 97.2 
UCL$ (%) 115.9 108.8 106.4 
P§ 0.424 0.258 0.369 
#Spike plus content of insulin-depleted serum 
$LCL = lower confidence limit; UCL = upper confidence limit (both two-sided with 95% P) 
§Probability of the 1-sample t-test 
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III.3.3. Method comparison study 
 
The results of the method comparison study are summarized in Figures III.10-13. Figure 
III.10 shows the scatter and absolute difference plot before recalibration for each 
immunoassay. In Figure III.11, the combined scatter and absolute difference plots before 
(A and B) and after recalibration with the respective weighted Deming equation (C and D) 
are given. Figures III.12 and 13 document the percentage difference plots after 
recalibration for the individual assays. They include the total error limit expected from the 
combined imprecision of the method pairs (Figure III.12) and the 32% total error limit 
(Figure III.13) as proposed by the ADA work group (3). The results are reported in mIU/L 
because the 4 manufacturers use different conversion factors for the calculation of results 
in mass units (µg/L or pmol/L). To convert the ID-LC/tandem MS results into IU, a relative 
molecular mass of 5807.6 and a factor of 6.945 for the conversion of mIU/L to pmol/L 
were used.  
 
Data before recalibration 
With ID-LC/tandem MS, the basal insulin concentrations ranged from 3.74 to 14.7 mIU/L, 
the stimulated concentrations from 1.83 to 247.6 mIU/L. The weighted Deming regression 
data for the method comparison are Roche = 1.21 (± 0.02, SE) x MS – 0.33 (±0.31) mIU/L 
(Sy/x 0.12 mIU/L), DPC = 1.27 (± 0.07) x MS + 0.74 (± 1.28) mIU/L (Sy/x 0.34 mIU/L), 
Beckman = 0.84 (± 0.01) x MS – 0.20 (± 0.12) mIU/L (Sy/x 0.09 mIU/L), and Abbott = 1.08 
(± 0.02) x MS – 0.33 (± 0.21) mIU/L (Sy/x 0.11 mIU/L). The observed bias is +20% for 
Roche, +42% for DPC, -17% for Beckman, and +6% for Abbott. The standard deviation of 
the differences of all assay results from ID-LC/tandem MS is 9.6 mIU/L (8.9 mIU/L without 
the DPC assay). The correlation data are r = 0.991 for Roche, r = 0.920 for DPC, r = 0.993 
for Beckman, and r = 0.992 for Abbott.  
Weighted Deming regression and correlation analysis of the method comparison 
data showed considerable between-assay variation, however, the correlation of those with 
the ID-LC/tandem MS is excellent with exception of the DPC assay. These data provide a 
reliable basis for the recalibration of the immunoassays based on the Deming regression 
equations (see below). 
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Figure III.10. Method comparison study between four immunoassays and ID-LC/tandem MS: for each 
immunoassay the scatter and absolute difference plot before recalibration is shown. 
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Data after recalibration 
Recalibration of the immunoassay results considerably reduced the between-assay 
variation. It reduced the standard deviation of the differences of all assay results from ID-
LC/tandem MS from 9.6 µIU/mL to 5 µIU/mL (from 8.9 µIU/mL to 3.4 µIU/mL without the 
DPC assay) (compare also panels A and B with panels C and D). Note that the variation 
in the recalibrated data is dominated by the DPC assay.  
 
 
 
 
Figure III.11. Combined scatter and absolute difference plots before (A and B) and after (C and D) 
recalibration with the respective weighted Deming equations. 
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Recalibrated data and expected total variation 
For a more detailed investigation of the residual spread of the data after recalibration, the 
% difference plots after recalibration shall be used (Figure III.12). This Figure includes 
also the expected spread of the data if only the imprecision of the respective method pairs 
is considered (see also Table III.7).  
Except for the DPC assay, 95% of the differences between the recalibrated data 
and the ID-LC/Tandem MS method lie within the expected total variation of the method 
comparison. This indicates sample related effects for the DPC only. Most probably, this 
assay suffers from specificity problems. 
 
Table III.7. Total imprecision corresponding to each method, to the method pair and 95% expected interval for 
the method comparison results. 
 
 CVtotal CVmp 1.96 x CVmp 
MS 12.1 - - 
DPC 7.3 14.1 27.7 
Roche 4.9 13.1 25.6 
Abbott 5.3 13.2 25.9 
Beckman 5.6 13.3 26.1 
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Figure III.12. Percentage difference plots after recalibration for each individual immunoassay. The dotted lines 
represent the 95% expected interval (1.96xCVmp). 
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Recalibrated data and ADA total error limit 
Figure III.13 shows that, after recalibration, all assays, with the exception of DPC, fulfill the 
total error specification of 32% set by the ADA work group (3). This demonstrates that the 
state-of-the-art of insulin immunoassays is quite good and that their standardization by ID-
LC/Tandem MS may provide a major step forward to accurate measurement of serum 
insulin by the immunoassay technique. It should be noted further that the MS 
measurements have been done only once. An even better outcome may be expected for 
the ADA panel where the MS measurements are done in four-fold (four independent 
measurements on four different days). 
 
 
 
 
Figure III.13. Percentage difference plots after recalibration for each individual immunoassay. The dotted lines 
at +32% represent the total error specification proposed by the ADA work group. 
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III.4. CONCLUSION  
 
In conclusion, we were able to develop an LC/tandem MS measurement procedure for 
human insulin in serum that was superior in terms of sensitivity in comparison to previous 
methods described in the literature. 
Our pilot study demonstrated that recalibration of insulin assays by regression 
equations established from method comparison with ID-LC/tandem MS can result in 
successful standardization and fulfillment of the total error criterion proposed by the ADA 
work group. 
 
III.5. CURRENT WORK  
 
Currently, the method is used for the certification of 40 single donation and 5 serum pools 
to be used for standardization of insulin immunoassays. This work is done under an ADA 
grant (29). Unfortunately, at this point, the ADA did not give consent to use the data in the 
current thesis. Therefore, only some general statements can be made about the progress 
of the method since. 
The accuracy and precision study demonstrated that an improvement of the CVtotal 
was desirable (range of 5 – 12%). This was achieved during the current study. The typical 
CVtotal (four independent measurements on four different days) for the measurement of the 
ADA panel was 2 - 3%, with somewhat increased values in the low concentration range (4 
- 6%; 100 ng/L range). This was reached by preparing the insulin standards in insulin free 
serum. However, this required to taking the standards through analysis. 
 
Also, the method had a relatively low total recovery (approximately 30 – 40 %). We 
could increase the recovery to 60 – 70% by performing the IAC at room temperature 
instead of at 4 °C. 
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Summary 
 
As explained in Chapter I, this thesis entirely fits into establishing the 'metrological 
traceability' of in-vitro diagnostic systems. Starting with a number of metrological 
considerations on measurements and measurement results in the clinical laboratory, the 
first chapter immediately addresses the problem of poor inter-laboratory and inter-method 
comparability of measurement results and continues with the generally accepted concept 
to solve this problem. This concept comprises the establishment of SI-traceability of 
commercial in-vitro diagnostic systems based on the use of a 'reference measurement 
system' as part of a traceability chain. The structure and elements of such a traceability 
chain are discussed in detail, as is its application. In this regard, it is clarified that 
traceability is the key to trueness/accuracy of a measurement result. Because reference 
measurement procedures are essential parts of a reference measurement system, this 
chapter also deals with the requirements and analytical specifications such measurement 
procedures have to meet in more detail, as well as with the internationally accepted 
mechanisms ("Joint Committee for Traceability in Laboratory Medicine" and dedicated ISO 
standards) to identify adequate reference measurement procedures and competent 
reference laboratories. At this point a first reference is made to the suitability of the 
technique of isotope dilution-mass spectrometry (ID-MS) to serve as a reference 
measurement procedure for quantification of organic compounds. It is also emphasized 
that doing a method comparison with a reference measurement procedure on native sera 
is the best way to establish traceability of a routine diagnostic system. As described in a 
later passage in this chapter, the development and application of ID-MS reference 
measurement procedures are two of the major objectives of this dissertation. The context 
in which these objectives are described is the so-called 'diabetes epidemic' that gradually 
affects humans worldwide and consequently increases the interest for routine C-peptide 
and insulin determinations. After addressing briefly the importance of laboratory 
investigations, this chapter immediately repeats the problem of non-comparability of 
measurement results. Although the clinical laboratory community found an intermediate 
solution to the problem, i.e., using method-dependent reference intervals, the need for 
establishing better comparability remained great. This need has even increased since 
authoritative organizations such as the American Diabetes Association (ADA) have aimed 
at publishing general guidelines and decision criteria with regard to the diagnosis of 
diabetes and therapeutic monitoring. Recently, the pharmaceutical industry increased the 
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necessity as a result of the development of new drugs (the so-called insulin sensitizers), 
which are recommended for therapy on the basis of the homeostasis model assessment 
(HOMA) insulin-resistance indices. In view of the considerations and explanation given in 
Chapter I, it is obvious that the need can be satisfied through the development of a 
reference measurement system, in order to make serum C-peptide and insulin 
measurements SI-traceable. Since at the start of this dissertation, to the best of our 
knowledge, the necessary reference measurement systems and traceability chain did not 
exist and the development of a reference measurement procedure for C-peptide and 
insulin became our first objective. A second objective consisted on demonstrating the 
utility of the respective reference measurement procedures in a method comparison with 
representative routine diagnostic systems. To be able to apply this method comparison on 
authentic patient samples, cooperation with the Department for Hormonology of the Ghent 
University Hospital was established. The major objectives of this dissertation fit excellently 
with those of the ADA Task Force and the National Institute of Diabetes & Digestive & 
Kidney Diseases (NIDDK). Indeed, because the activities of the latter groups did not 
succeed in terms of metrological traceability, they recently called upon trueness-based 
standardization of C-peptide and insulin measurements. As a result an award was granted 
to our laboratory for the research towards an insulin reference measurement procedure. 
Finally, this chapter describes in a detailed way the focus of our research to reach the 
aforementioned objectives. The distinct steps are discussed in detail in the Chapters II 
and III. 
 Chapter II deals with the development, validation and application of a reference  
measurement procedure for C-peptide in serum. By way of introduction the biosynthesis, 
secretion and metabolism of C-peptide in humans is described in short. In view of the 
close relationship between C-peptide and insulin, both of which originate from the 
common precursor proinsulin, this introduction in the C-peptide chapter is extended also 
to insulin. The same applies for the discussion of the physiological effects and the clinical 
applications of laboratory measurements. With regard to the latter, specifically for C-
peptide, an overview of the existing measurement procedures is given. Besides those for 
routine use, also  chromatographic and mass spectrometric procedures, some of them in 
the combined mode, are discussed, in particular because the latter will served as a basis 
for the development of the aimed reference measurement procedure. These 
developments are systematically described. They focus in particular on the specificity for 
interference-free analysis of C-peptide in the serum matrix and on the achievement of 
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sufficient sensitivity for measurement of concentrations typical within the 
physio(patho)logy of C-peptide. Also the analysis time and robustness of the 
measurement procedure played an important role. Specifications for total precision, 
trueness and limit of quantification were set by ourselves. In the C-peptide study special 
attention was paid to the collision induced dissociation (CID) of the doubly charged 
deprotonated molecular ion [M–2H]2- of C-peptide. On the basis of the experiments and 
their evaluation, we finally opted for an isotope dilution-liquid chromatography/tandem 
mass spectrometry (ID-LC/tandem MS) procedure after serum purification with solid 
phase extraction in two steps. For MS detection we worked under conditions of negative 
electrospray ionization (ESI) and high-energy CID of the [M-2H]2- C-peptide/D8-Val7,10-C-
peptide molecule (transitions from m/z 1509.2 to 183.8 and 1517.1 to 183.8, respectively). 
Validation of the most important analytical characteristics of the selected ID-LC/tandem 
MS procedure proved that it met the preset requirements and specifications. With regard 
to the second objective, our study confirmed the need for standardization of C-peptide 
routine measurement procedures. It also documented that standardization via a method 
comparison between the developed ID-LC/tandem MS measurement procedure and the 
routine test systems on authentic patient samples was feasible. The performance of the  
tested routine systems after recalibration was estimated against specifications. This 
chapter is finalized by giving perspectives concerning further activities and/or 
requirements for state-of-the-art standardization at the international level. 
 In Chapter III the development of a reference measurement procedure for insulin 
on the basis of ID-LC/MS is discussed. The research is conducted in the same way as 
described for C-peptide, i.e., by starting from existing LC/MS measurement procedures 
and seeking for a sensitive and specific reference measurement procedure, that satisfies 
the specifications for total precision, trueness and limit of quantification defined by the 
ADA. Since this research was conducted together with a colleague, it must be mentioned 
that the outcome of the experiments done and described as part of this dissertation, is not 
necessarily withheld in the final measurement procedure (e.g., the two-step solid phase 
extraction was finally substituted with a combined immuno affinity-solid phase extraction). 
During the method optimization experiments with various collision gasses in two different 
MS configurations were done in order to increase sensitivity. Special attention was paid to 
the stability of the standard solutions. The relationship between the commercial standard 
material (used for the calibration of our measurement procedure) and the WHO standard 
(used by the in-vitro diagnostic companies as calibration basis) was investigated. On the 
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basis of the combined results of all experiments presented in this dissertation and the one 
of a colleague, we finally opted for an ID-LC/tandem MS procedure with a sample 
preparation procedure based on a combined immunoaffinity chromatography-solid phase 
extraction. For the LC procedure we opted for alkaline gradient elution with ammonia on 
an basic-pH resistant stationary phase in combination with wrong way round positive ESI 
mode and monitoring of the transition of the four-times protonated molecular ions 
[M+4H]4+  from m/z 1453 to 226 (insulin) and from m/z 1463 to 226 (4-[D10]Leu-insulin). 
As a result of these LC/tandem MS conditions a remarkable increase in the sensitivity was 
observed in comparison with the existing measurement procedures operated under 
conventional conditions (acidic mobile phase and positive ESI). The validation of the 
analytical characteristics of the selected measurement procedure showed that they met 
the ADA specifications, apart from the imprecision component. Like in the C-peptide 
study, we showed the utility of the ID-LC/tandem MS procedure for method comparison. 
After recalibration of the tested routine systems it was possible on the basis of this method 
comparison, to investigate their performance against the ADA specifications for total error 
derived from the biological variation of insulin in human. For the tested insulin systems the 
impact of the recalibration from the method comparison was considered rather moderate. 
This chapter is concluded with the perspective that our ID-LC/tandem MS procedure will 
be used by the ADA for standardization of commercial insulin routine procedures. 
Unfortunately, at this point, the ADA did not give consent to use the data in the current 
dissertation. Therefore, only general statements have been made about the progress of 
the measurement procedure since.  
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Samenvatting 
 
Zoals in Hoofdstuk I  uitgelegd, kadert deze thesis integraal in de verwezenlijking van  
'metrologische herleidbaarheid' van in-vitro diagnostische systemen. Vanuit een aantal 
algemene metrologische beschouwingen rond metingen en meetresultaten in het klinisch 
laboratorium, wordt in dit hoofdstuk onmiddellijk de problematiek van onvoldoende 
vergelijkbaarheid van meetresultaten tussen methoden en laboratoria aangesproken, om 
vervolgens het algemeen aanvaarde concept tot oplossen van deze problematiek voor te 
stellen. Dit concept bestaat in het verwezenlijken van SI-herleidbaarheid van commerciële 
in-vitro diagnostische systemen via aanwenden van een 'referentiemeetsysteem' als 
onderdeel van een herleidbaarheidsketen. De structuur en de elementen van zo'n 
herleidbaarheidsketen worden in detail besproken, evenals de aanwending ervan. In dit 
verband wordt duidelijk gemaakt dat herleidbaarheid de enige sleutel tot 
juistheid/nauwkeurigheid van een meetresultaat is. Aangezien referentiemeetprocedures 
essentiële onderdelen van een referentiemeetsysteem zijn, gaat dit hoofdstuk ook dieper 
in op de vereisten en analytische specificaties waaraan dergelijke meetprocedures 
moeten voldoen, evenals op de internationaal aanvaarde mechanismen ("Joint Committee 
for Traceability in Laboratory Medicine" en specifieke ISO standaarden) om adequate 
referentiemeetprocedures en competente referentielaboratoria  te identificeren. Hier wordt 
reeds een eerste keer verwezen naar de geschiktheid van de techniek van isotoop dilutie-
massaspectrometrie (ID-MS) als basis voor een referentiemeetprocedure van organische 
componenten. Tevens wordt benadrukt dat voor het realiseren van herleidbaarheid van 
een routine diagnostisch systeem, deze laatste best aan een methodevergelijking met de 
referentiemeetprocedure en gebruik van natieve sera wordt onderworpen. Zoals verder in 
dit hoofdstuk beschreven, behoort de ontwikkeling en toepassing van ID-MS 
referentiemeetprocedures trouwens tot de hoofdobjectieven van deze thesis. De context 
van deze objectieven is de zogenaamde 'diabetes epidemie' die wereldwijd toeslaat en 
maakt dat diagnostisch gezien de interesse voor routine C-peptide en insulinebepalingen 
in humaan serum gestaag toeneemt. Na een korte uiteenzetting van het belang van deze 
laboratoriumbepalingen, komt dit hoofdstuk onmiddellijk terug op de problematiek van 
niet-vergelijkbaarheid van meetresultaten. Ofschoon de klinische 
laboratoriumgemeenschap zich aan dit probleem heeft aangepast door o.a. het gebruik 
van methodeafhankelijke referentie-intervallen, is de nood tot verwezenlijken van betere 
vergelijkbaarheid zeer groot, des te meer aangezien gezaghebbende organisaties zoals 
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de "American Diabetes Association" (ADA) willen overgaan tot het uitvaardigen van 
algemene richtlijnen en beslissingscriteria in verband met de diagnose van diabetes en/of 
opvolgen van de therapie. Recent heeft ook de farmaceutische industrie zich bij deze 
nood geschaard, meer bepaald sedert de ontwikkeling van nieuwe geneesmiddelen (de 
zogenaamde insuline "sensitizers"), die therapeutisch aanbevolen worden op basis van 
indexen voor insulineresistentie, zelf afgeleid uit "homeostasis model assessment" 
(HOMA). Vanuit de overwegingen en uitleg in Hoofdstuk I is het duidelijk dat deze nood 
kan gelenigd worden door de ontwikkeling van een referentiemeetsysteem om zowel 
serum C-peptide als insulinemetingen SI-herleidbaar te maken. Aangezien bij het 
aanvatten van deze thesis, voor zover wij er kennis van hadden, de noodzakelijke 
referentiemeetsystemen en herleidbaarheidsketens onbestaande waren, werd de 
ontwikkeling van een referentiemeetprocedure voor C-peptide en insuline ons eerste 
objectief. Een tweede objectief bestond erin de bruikbaarheid van de respectievelijke 
referentiemeetprocedures in een methodevergelijking met representatieve routine 
diagnostische systemen aan te tonen. Om deze methodevergelijking op authentieke 
patiëntenstalen te kunnen doen, werd een  samenwerking met het Departement voor 
Hormonologie van het Universitair Ziekenhuis te Gent tot stand gebracht. De voornoemde 
objectieven sloten zeer goed aan bij de objectieven van o.a. de ADA "Task Force" en de 
"National Institute of Diabetes & Digestive & Kidney Diseases" (NIDDK). Inderdaad, 
aangezien de activiteiten van laatstgenoemde groepen tot nog toe geen succes in termen 
van metrologische herleidbaarheid hadden opgeleverd, hadden zij recent nog een oproep 
gedaan tot juistheidgebaseerde standaardisatie van C-peptide en insulinemetingen. Op 
die manier kwam zelfs voor ons laboratorium een financiële ondersteuning van het 
wetenschappelijk onderzoek naar een insulinereferentiemeetprocedure tot stand. Tot slot 
wordt in dit hoofdstuk gedetailleerd uiteengezet op wat het wetenschappelijk onderzoek 
zich zou toespitsen om voornoemde objectieven te bereiken. De verschillende stappen in 
dit onderzoek komen in de Hoofdstukken II en III uitgebreid aan bod.   
 In Hoofdstuk II wordt de ontwikkeling, validatie en toepassing van een 
referentiemeetprocedure voor C-peptide in serum behandeld. Bij wijze van inleiding wordt 
de biosynthese, secretie en het metabolisme van C-peptide bij de mens kort besproken. 
Gezien de verwantschap van C-peptide en insuline vanuit de gemeenschappelijke 
precursor, het proinsuline, wordt de inleiding van het C-peptidehoofdstuk met insuline 
uitgebreid. Hetzelfde geldt voor de bespreking van de fysiologische effecten en het 
klinisch toepassen van laboratoriummetingen. In dit laatste verband wordt vervolgens 
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specifiek voor C-peptide een overzicht van de bestaande meetprocedures gegeven. 
Naast deze voor routinegebruik worden ook chromatografische en 
massaspectrometrische procedures, al dan niet gecombineerd, besproken, vooral omdat 
deze laatste als basis zullen dienen bij de  ontwikkeling van de beoogde 
referentiemeetprocedure. Deze ontwikkelingen worden stapsgewijs besproken. Zij 
spitsten zich vooral toe op de specificiteit voor interferentievrije analyse van C-peptide in 
de serummatrix, op het bereiken van  voldoende gevoeligheid voor meting van 
concentraties typisch voor de fysio(patho)logie van C-peptide. Ook de analysetijd en de 
robuustheid van de meetprocedure speelden een belangrijke rol. Specificaties voor totale 
precisie, juistheid en bepaalbaarheidsgrens werden door onszelf vooropgesteld. Een 
speciaal aandachtspunt in de C-peptidestudie was de collisie-geïndiceerde dissociatie 
(CID)  van het tweevoudig geladen gedeprotoneerde moleculair ion [M–2H]2- van C-
peptide. Op basis van de doorgevoerde experimenten en hun beoordeling werd finaal 
geopteerd voor een ID-LC/tandem MS procedure, na serumopzuivering via vaste fase-
extractie in twee stappen. Voor MS-detectie werd gewerkt onder voorwaarden van 
negatieve elektrospray ionisatie (ESI) en hoge-energie CID van de [M-2H]2- C-peptide/D8-
Val7,10-C-peptide molecule (transities van m/z 1509.2 tot 183.8 en 1517.1 tot 183.8, 
respectievelijk). De validatie van de voornaamste analytische karakteristieken van de 
geselecteerde ID-LC/tandem MS procedure bewees dat zij voldeed aan de door ons 
vooropgestelde eisen en specificaties. In verband met het tweede objectief, bevestigde 
onze studie de nood aan standaardisatie van C-peptide routinemeetprocedures. Zij 
toonde tevens aan dat deze standaardisatie via een methodevergelijking tussen de 
ontwikkelde ID-LC/tandem MS meetprocedure en de routine testsystemen op authentieke 
patiëntenstalen mogelijk is. De performantie van de geteste routinesystemen na 
recalibratie werd tegen specificaties beoordeeld. Dit hoofdstuk wordt afgesloten met de 
formulering van een aantal perspectieven over wat er nog te doen staat om de feitelijke 
standaardisatie op internationaal niveau volgens de regels van de kunst uit te voeren. 
 In Hoofdstuk III wordt de ontwikkeling van een referentiemeetprocedure voor 
insuline op basis van ID-LC/MS besproken. Het wetenschappelijk onderzoek wordt 
grotendeels volgens hetzelfde stramien als beschreven voor C-peptide uitgevoerd, meer 
bepaald door uitgaande van de bestaande LC/MS meetprocedures te zoeken naar een 
gevoelige en specifieke referentiemeetprocedure, die voldoet aan specificaties voor totale 
precisie, juistheid en bepaalbaarheidsgrens vooropgesteld door de ADA. Aangezien dit 
onderzoek in samenwerking met een collega gebeurde, werd het resultaat van de 
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experimenten in deze thesis uitgevoerd en beschreven, niet noodzakelijkerwijze in de 
finale meetprocedure weerhouden (bv. de tweestaps vaste fase-extractie werd in de finale 
procedure gesubstitueerd met een gecombineerde immunoaffiniteits-vaste fase-extractie). 
Speciale aandachtspunten in de insulinestudie waren de CI dissociatie met verschillende 
collisiegassen in twee verschillende MS configuraties, de stabiliteit van de 
standaardoplossingen en het verband tussen het commerciële standaardmateriaal, dat wij 
ter calibratie van onze meetprocedure gebruikten, en de WHO-standaard, die door de in-
vitro diagnostica firma's als calibratiebasis wordt gebruikt. Op basis van de 
gecombineerde resultaten van alle experimenten (in deze thesis en die van een collega) 
werd finaal geopteerd voor een ID-LC/tandem MS procedure, na serumopzuivering via 
een gecombineerde immunoaffiniteitschromatografie-vaste fase-extractieprocedure. Voor 
de LC procedure werd geopteerd voor een alkalische gradiëntelutie met ammonia op een 
hoge pH-bestendige stationaire fase in combinatie met "wrong way round" positieve ESI, 
waarbij de transitie van de viervoudig geprotoneerde moleculaire ionen [M+4H]4+  van m/z 
1453 tot 226 (insuline) en 1463 tot 226 (4-[D10]Leu-insuline) werden gevolgd. Het 
resultaat van deze LC/tandem MS condities was een opmerkelijke toename van de 
gevoeligheid in vergelijking met de bestaande meetprocedures op basis van klassieke 
zure positieve ESI LC/MS. Na  validatie van de analytische karakteristieken konden wij 
bewijzen dat de geselecteerde meetprocedure voldeed aan de ADA specificaties, op 
vooral de imprecisiecomponente na. Net zoals bij de C-peptidestudie werd de 
bruikbaarheid van de ID-LC/tandem MS procedure voor  methodevergelijking in een 
toepassing gedemonstreerd. Na recalibratie van de geteste routinesystemen op basis van 
deze methodevergelijking was het mogelijk hun performantie tegen de ADA specificaties 
voor totale fout op basis van de biologische variabiliteit voor insuline te beoordelen. 
Opmerkelijk was dat voor de geteste insulinesystemen de impact van de recalibratie op 
basis van de methodevergelijking niet zo ingrijpend was als voor de C-peptidesystemen. 
Dit hoofdstuk wordt afgesloten met het perspectief dat de ID-LC/tandem MS procedure 
door de ADA als basis voor de standaardisatie van de commerciële insuline 
routineprocedures zal gebruikt worden, waarvoor de ADA echter tot op heden geen 
toestemming tot gebruik in deze thesis gaf. Daarom kunnen slechts een aantal algemene 
gegevens over de verdere vorderingsstaat van de studie worden gegeven. 
 
 
 
